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Age-related macular degeneration (AMD) and diabetic eye disease are two of 
the main causes for blindness and severe visual loss in developed countries.  Late 
AMD may be in the exudative, or neovascular form, whilst the main cause of 
visual loss in diabetic eyes is caused by an increase in microvascular endothelial 
permeability which leads to macular oedema. Treatment outcomes have 
improved considerably with the introduction of intravitreal therapies that inhibit  
vascular endothelial growth factor (VEGF). However, the advanced form of 
macular diseases, can result in a progressive and irreversible loss of the central 
retina, affecting central vision including the capacity to fixate. In contemporary 
clinical practice, assessment of retinal pathologies typically includes visual 
acuity, fundal examination, and optical coherence tomography (OCT), which has 
been established as the gold standard for the management of retinal pathologies. 
However, since it is a diagnostic technique based exclusively on the structural 
image, it does not offer the possibility of evaluating functional data regarding 
visual function. Microperimetry (MP) technology assess functional 
characteristics of the retina, however is not commonly used in retinal clinical 
practices. This research poses two questions related the use of MP: the 
optimisation and standardisation in the clinical practice. It aims to understand 
and clarify the benefits of retinal functional analysis performed with the latest 
generation of MP instruments.  
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The macula is the central part of retina, the centre of which is the fovea. The 
fovea is responsible for detailed vision, colour perception, and fixation 
capabilities. Some of the major diseases that affect the macula, such as dry age-
related macular degeneration (AMD), Stargardt’s disease and other similar 
pathologies, progress slowly and cause mild blurring of central vision in the early 
or intermediate stages of the pathology. The advance stage of dry AMD may 
affect large areas of the central retina causing central vision loss commonly 
resulting in poor vision and unstable fixation. AMD progression may result in 
significant visual impairment.  
 
The advanced stage of AMD and other similar pathologies affecting the macula 
have no available proven treatment to date. Individuals with late stage macular 
pathologies can only improve their residual vision and quality of life through 
vision rehabilitation services. The typical rehabilitation process for patients with 
foveal involvement secondary to late stage AMD has included the use of prisms, 
magnifiers and other non-technological aids as mobility training, counselling 
and education. 
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The accurate control of eye movements involves several different structures, 
from the extraocular muscles to the frontal cortex of the brain. There are three 
major types of eye movement. Smooth pursuit, or the following of a target 
accurately; Saccadic eye movements, where a sudden shift of the eyes to a new 
target occurs; and Sustained gaze, where the eyes are fixed in one direction to a 
specific visual target.  
 
In healthy eyes, the anatomical area of the retina used to fixate is the fovea, as 
described previously. In cases of eyes with central vision loss, fixation attempt 
is performed with an eccentric retinal area known as the Preferred Retinal Locus 
(PRL). However, retinal loci of fixation in these eyes are not always optimal for 
the best visual performance and result, in most cases, in constant involuntary eye 
movement with unstable fixation. In essence, peripheral (eccentric) PRLs are 
associated with highly unstable fixation and very poor visual acuity, where 
fixation stability decreases whilst PRL eccentricity increases (Von Noorden and 
Mackensen, 1962, Sullivan et al., 2008). 
 
Biofeedback is a therapeutic technique used to increase awareness of a 
physiological function. Biofeedback methods used in rehabilitation are based on 
biomechanical measurements and measurements of the physiological systems of 
the body, the neuromuscular system, the respiratory system and the 
cardiovascular system. Biomechanical feedback can be obtained through 
different physical measurements, such as movement, postural control and force 
output. Biofeedback is generally delivered using visual displays, acoustic or 
haptic signals, however more recently virtual reality (VR) or exergaming 
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technology have been used as biofeedback signals. Biofeedback has shown to be 
effective in improving exercise technique in musculoskeletal populations. While 
a number of studies in this area have been conducted, further large scale studies 
and reviews investigating different biofeedback applications in different clinical 
populations are required (Giggins et al., 2013). 
 
Biofeedback rehabilitation in ophthalmology is seldom used, nonetheless few 
authors have reported its use in patients with unstable fixation secondary to 
central vision loss. This technique is based on the theory of neural plasticity 
where areas of residual vision can be identified and repetitively stimulated, 
improving ocular motor control for better residual visual performance. In recent 
years a biofeedback therapy has been incorporated in microperimetry devices, 
with the purpose to improve eccentric visual function in cases of maculopathies 
affecting the central macula. 
 
Microperimetric biofeedback training is a visual rehabilitative strategy based on 
fixation stability improvement, reinforcing or creating a new preferential 
fixation locus. The rationale consists in re-educating the visual system to a new 
visual condition, promoting retina-brain transmission, and thus cortical 
plasticity. Its major application in visual diseases is related to macular 
pathologies affecting central vision, however this therapeutic process is still 
limited due to poor knowledge of the procedure and inconsistent standards of 
practice, which implies an incipient scepticism on its efficacy (Vingolo et al., 
2018). 
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The first Microperimeter with Biofeedback rehabilitation software (Nidek-
MP1), was introduced in 2003 by Nidek Technologies (Padova, Italy). 
Unfortunately, the rehabilitation method of the MP1 was not widely used due to 
the difficulty of operation and the high cost of the instrument. More recently, 
Centervue (Padova, Italy) developed a 3rd generation of microperimetry 
systems, the Macular Integrity Assessment (MAIA). The biggest advantage of 
the MAIA is the ease of operation and the much lower cost than similar 
instruments of its kind. Although few authors have suggested the effectiveness 
of biofeedback eccentric visual training with both the MP1 and the MAIA, the 
methodology of such therapeutic process has never been properly described or 
correlated in a large cohort of patients. As such there are several open questions 
about this technique that have limited its use to few international experts. 
 
For years microperimetry (MP) technology has been confined to the use of few 
specialist and researchers due to the complexity of the previous technology.  This 
research aims to understand and clarify the benefits of retinal functional analysis 
performed with the latest generation of MP instruments.  
 
 
1.2 Aims and Objectives 
  
This research poses two questions related the use of MP: the optimisation and 
standardisation in the clinical practice. It aims to understand and clarify the 
benefits of retinal functional analysis performed with the latest generation of MP 
instruments.  
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The purpose of the present study is to analyse retinal functional characteristics 
such as light threshold sensitivity, fixation location and fixation stability with 
MP, in common macular diseases including AMD, and determine its value in 
monitoring disease progression, treatment and visual rehabilitation of macular 
diseases.  
 
The study has 2 main sections: 
 
a) MP in the monitoring of macular diseases. 
The aim of this section is to assess the benefit of MP functional analysis in 
clinical practice for patients undergoing surgical or clinical treatments, related 
to pathologies affecting central vision, such as AMD, diabetes macular oedema 
(DMO), macular oedema secondary to retinal vein occlusions (RVO), macular 
holes (MH) and epiretinal membranes (ERM). This study may allow a better 
understanding of retinal functional characteristics, complementing existing 
standard eyecare tests, aimed at predicting better prognosis for patients with 
different macular pathologies, such as the OCT structural analysis, and the well-
known visual acuity (VA) test. 
 
b) Eccentric fixation training for visual rehabilitation with MP biofeedback 
technology. 
This section analyses MP biofeedback fixation training (BFT) as a visual 
rehabilitation process in patients with loss of central vision, with the aim of 
studying the effectiveness of such technology and proposing guidelines for this 
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rehabilitation method, allowing the use of this technique to a wider pool of eye 
specialists with minimal experience in eccentric vision rehabilitation. In this 
section, the different variables responsible for unstable fixation, and the selection 
of the best eccentric functional retinal locus will be studied. The definition of the 
best eccentric functional retinal locus, may lead to better outcomes in other 
vision therapies commonly performed in low vision centres, increasing 
possibilities for a better quality of life in patients with loss of central vision 
secondary to macular pathologies.  
 
 
1.3 Structure and function of the retina 
 
The Retina 
In normal eyes, light rays enter the eye through the cornea, the pupil and through 
the crystalline lens to converge into a sharp focusing point on the retina. The 
retina is a delicate sheet of nervous tissue located in the posterior wall inside the 
eye. It is formed of several layers of nerve cells interconnected by synapses, 
which sense light (visual information) that is converted into electrical signals 
that are transmitted along the optic nerve to the brain. The outer surface of the 
retina is in contact with the choroid; the inner surface is adjacent to the vitreous 
body. The neural retina forms the inner layer of the retina where neural cells 
(photoreceptor, bipolar, and ganglion cells) are located. The retinal pigment 
epithelium (RPE) forms the thin outer retina which supports the retinal 
photoreceptors. The neural retina is anchored only at the optic disc, where nerve 
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fibres congregate before passing through the sclera to form the optic nerve 
(Krause, 2005). 
 
Histologically, the retina can be divided into 10 detailed layers (Kolb et al., 1995, 
Krause, 2005, Willermain et al., 2014). From the inner to the outer part of the 
retina, these retinal layers are organized as follows. The inner limiting membrane 
(ILM) is formed by the conical end of the Müller cells and astrocytes. The nerve 
fibre layer (NFL) consists of axons of ganglion cells, retinal vessels and glial 
cells. The ganglion cell layer (GCL) predominantly contains the nucleus of 
ganglion cells, vessel cells, glial cells, and some displaced amacrine cells. The 
inner plexiform layer (IPL) where bipolar, amacrine, and ganglion cells interact. 
The inner nuclear layer (INL) harbours the nuclei from bipolar, horizontal, 
amacrine, and Muller cells. The outer plexiform layer (OPL) is where 
photoreceptor cells connect with bipolar cells, and where horizontal cells interact 
closely with both photoreceptors and bipolar cells. The outer nuclear layer 
(ONL) contains nuclei from photoreceptor cells. The external limiting 
membrane (ELM) is created by junctional complexes between adjacent Muller 
cells as well as between Muller and photoreceptor cells. The photoreceptor layer 
(PL) contains tightly stacked cones and rods forming a palisading layer of 
photoreceptors. The tenth layer results from tight junctional complexes between 
RPE cells forming a continuous RPE monolayer. Moreover, the RPE is separated 
from the choriocapillaris by the Bruch’s membrane composed of 5 layers: the 
basement membrane of the choriocapillaris, an outer collagenous layer, a central 
elastic layer, an inner collagenous layer, and the basement membrane of the RPE. 
The RPE absorbs light after it has passed through the neural retina and prevents 
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reflection within the eye. It is a storage site for vitamin A, a precursor of 




Vascular Supply of the Retina 
The inner layers of the retina are supplied by retinal vessels arising from the 
central retinal artery, which enters the eye in the optic nerve. Capillary networks 
from this source lie in the nerve fibre layer and in the inner plexiform layer. The 
outer nuclear and plexiform layers and the layer of rod and cone inner segments 
lack blood vessels. These parts of the retina are nourished by diffusion of 
nutrients from capillaries of the choriocapillaris layer of the choroid. Nutrients 
Figure 1.1  OCT image of a normal retina 
Measurement areas for macula Early Treatment Diabetic Retinopathy Study grid 
(A), and macula 6 circle (B). Single-frame OCT B-scan images overlaid with 
boundaries (green and blue lines) demonstrated the retinal layers in various 
retinal thickness measurements, including full retinal thickness (C); ganglion 
cell + inner plexiform layers (distance between the 2 green boundaries), 
ganglion cell complex (distance between the blue and green boundaries, vitreal 
to inner nuclear layer) (D).(Chaglasian et al., 2018) 
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cross the pigmented epithelium to enter the intercellular spaces of the outer 
neural retina (Krause, 2005). 
 
Photoreceptors 
The photoreceptor cells are directly sensitive to light. There are two types of 
photoreceptors in the human retina, rods and cones. Rods function mainly in dim 
light (scotopic vision) with low spatial acuity and do not mediate colour vision. 
Cones are active at higher light levels (photopic vision), mediate colour vision 
and provide high spatial acuity. The light levels where both are operational are 
called mesopic (Kawamura and Tachibanaki, 2012). The human cone 
photoreceptor distribution has a high peak packing density at the foveal centre, 
which decreases rapidly within the central 2 mm of retina. Cone density 
decreases as rod density increases longitudinally from the fovea to the retinal 
periphery (Song et al., 2011). Recent studies confirmed that cone photoreceptor 
density decreases at 1, 2, 4 and 6 degrees of eccentricity, showing a homogenous 
drop in each of the four retinal meridians and high agreement between nasal and 
temporal locations (Song et al., 2011, Lombardo et al., 2013). 
 
The Macula & Fovea 
The anatomic macula of the eye is the area of retina extending from the temporal 
optic disc margin, and enclosed by the supero-tempral and infero-temporal 
retinal blood vessels. The central part of the retina, known as the macula lutea, 
is a flattened oval area in the centre of the retina approximately 3 to 4 mm (15°) 
temporal to and slightly below the optic disc. The macula appears as a yellow, 
oval area, when examined under green light. Its diameter is roughly equal to that 
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of the optic disc (1.5–1.9 mm). Located in its centre is the avascular fovea 
centralis, a funnel-like depression in direct line with the visual axis. The fovea 
centralis is populated exclusively by cones (no rods), which explains why it is 
the point at which visual perception is sharpest. Foveal cones are longer and 
thinner than cones elsewhere in the retina. Light stimuli in this region can 
directly act on the sensory cells, as retinal layers beyond the outer nuclear layer 
are displaced laterally, giving light an almost free pathway to the photoreceptors 
(Lang, 2015). Detailed visual tasks, such as fixation, are only performed with 
the fovea in healthy subjects.  
 
Retinal Visual Processing 
Retinal visual processing starts when light photons pass through the neuroretina 
triggering a change in the excitatory signalling to bipolar cells and subsequently 
ganglion cells. Bipolar and ganglion cell responses are modulated by horizontal 
and amacrine cells responses, respectively. Ganglion cell axons converge to 
form the optic nerve which carries the signal to the brain (Lang, 2015). 
 
Visual Field 
Visual field (VF) can be defined as all the space that one eye can see (visualise) 
at any given instant. Perimetry is defined as the study of the VF, whilst any 
instrument design to measure VF is called a perimeter (Tate and Lynn, 1977). 
Although VF consists in a three-dimensional volume of space, it is represented 
in perimetry in two dimensions and is described as the “area” rather than the 
“volume”. The extent of the normal VF, measured in degrees, for a bright 
stimulus is 60° superior, 75° inferior, 100° temporal and 60° nasal. With both 
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eyes open the VF has a horizontal extent of approximately 200°. The binocular 
field is the region where both eyes can see contemporarily a stimulus.  
 
The sensitivity of the eye is not constant across the whole VF, it varies with 
eccentricity, the nature of the test stimuli and adaptation level, corresponding to 
photoreceptor density distribution. When the eye is light-adapted, the sensitivity 
peak is at its centre. When the eye is dark-adapted, sensitivity is more distributed 
eccentrically with lower values on the fovea due to the cone-rod distribution. 
 
 
1.4 Clinical features and treatments of common 
macular pathologies. 
 
Age Related Macular Degeneration (AMD) 
Age-related macular degeneration (AMD) is the leading cause of blindness and 
visual disability in the elderly across the developed world (Klein et al., 1999). 
There are 2 types of late AMD: dry and neovascular (wet) AMD (Ferris et al., 
2013). Vision performance in the late stage of AMD is regularly decreased due 
to the loss of central vision. Late stage AMD is present in approximately 5% of 
over 65’s and 12% of over 80’s (Smith et al., 2001). By 2040, the number of 
individuals in Europe with early AMD will range between 14.9 and 21.5 million, 
and for late AMD between 3.9 and 4.8 million (Colijn et al., 2017). The 
worldwide projected number of people with AMD in 2020 is 196 million, 
increasing to 288 million in 2040 (Wong et al., 2014). 




AMD is a multifactorial disease involving ocular, systemic and genetic risk 
factors. The ocular risk factors include iris pigmentation and hyperopic 
refraction, while systemic risk factors include cigarette smoking, obesity, 
sunlight exposure and cardiovascular diseases (Chakravarthy et al., 2010, 
Choudhury et al., 2011). Genes influence several biological pathways related to 
AMD, including the immune processes, mechanisms involving collagen and 
glycosaminoglycans synthesis and angiogenesis. All these factors have been 
associated with the onset, progression and bilateral involvement of early, 
intermediate, and advanced states of AMD (Lombardo et al., 2012).  
 
Classification of AMD 
There are two clinical types of AMD, the “dry” and “wet” form. Early (dry) 
AMD progresses slowly and causes mild blurring of central vision in the early 
or intermediate stage of the pathology. In these stages, insoluble extracellular 
aggregates called drusen accumulate in the retina. The late stage of dry AMD, 
which is also known as Geographic Atrophy (GA), is characterized by scattered 
or confluent areas of degeneration of RPE cells and the overlying retinal 
photoreceptors, which rely on the RPE for trophic support. This late stage may 
also affect large areas of the central retina, causing the total loss of central vision 
(scotoma) with important decrease of visual acuity (VA).  
 
AMD may also progress (10–15%) in an exudative (wet) form, termed 
neovascular AMD (nvAMD) which is typified by development of choroidal neo-
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vascularization (CNV), where newly immature blood vessels grow toward the 
outer  retina from the underlying choroid with subsequent progression to the 
retina, and leak fluid below or within the intra retinal layers. Patients with sight 
loss due to nvAMD are expected to increase from 145,697 to 189,890 by the end 
of the decade in the U.K. (Minassian et al., 2011). 
 
AMD assessment 
Fundus fluorescein angiography (FFA) is the gold standard to diagnose CNV 
due to AMD. Leakage of dye (hyper-fluorescence) is noted and classified by 
location (subfoveal, juxtafoveal, or extrafoveal) and by type (classic, occult, or 
mixed). Dynamic high-speed indocyanine green angiography (ICG) improves 
identification and characterisation of neovascular variants of AMD (e.g., the 
polypoidal choroidal  vasculopathy) as it delineates the choroidal circulation 
more clearly than FFA (Chakravarthy and Williams, 2013). Optical coherence 
tomography (OCT) is excellent at detecting leaked fluid from abnormal vessels. 
It enables high-resolution in vivo cross-sectional or volumetric tomographic 
visualisation of the retinal micro-architecture. Although OCT outlines the 
neovascular choroidal complex, its components are difficult to distinguish from 
fibrous components, haemorrhages or dense exudates within the lesion. 
Similarly, OCT is not dynamic, and cannot detect the origin of leakage from 
abnormal vasculature. The newer modality of OCT angiography (OCT-A) may 
provide an advancement of OCT technology, and allow detection of leakage. 
With the advent of anti-VEGF therapy, OCT imaging is widely used for 
screening and early diagnosis of CNV, and for the monitoring of treatment 
outcomes and re-treatment management (Chakravarthy and Williams, 2013, 
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Ambati and Fowler, 2012). The sensitivity and specificity of OCT in diagnosis 
of nvAMD is lower than that of FFA (Castillo et al., 2015). 
 
In contemporary clinical practice, assessment of AMD, including re-treatment 
decisions in nvAMD, typically includes visual acuity, fundal examination, and 
OCT at monthly follow-up intervals (Chakravarthy and Williams, 2013). 
However, it is generally accepted that VA change or OCT alone may not be the 
optimum parameter(s) for measuring visual function in AMD and other macular 
diseases, as these are dependent on function in limited parts of the central 
macula. Thus, microperimetry systems may be considered a more reliable mean 
to assessing the sensitivity of the central retina due to the precise topographic 
correlations of macular anatomy and threshold light sensitivity, even in cases of 
highly unstable fixation capabilities (Rohrschneider et al., 1996, Midena et al., 
2004). 
 
Management of AMD 
Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) 
therapy have become the standard for treatment of CNV or nvAMD, as it can 
efficiently block the pathophysiological process of CNV, restore retinal 
morphology and increase/maintain neurosensory function in most patients with 
neovascular AMD (Rosenfeld et al., 2006). Current treatment options include 
bevacizumab (Avastin, Genentech, San Francisco, CA), ranibizumab (Lucentis, 
Genentech), and aflibercept (Eylea, Regeneron, Tarrytown, NY). They can be 
delivered at monthly intervals until stable, followed by different maintenance 
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regimen including 1-2 monthly fixed dosing, or pro re nata. However, no 
treatment has been proven to be effective in the management of dry AMD. 
 
Diabetic Retinopathy (DR) & Macular Oedema (DMO) 
Diabetes mellitus, commonly referred to as diabetes, is a metabolic disease in 
which the patient has a high serum glucose level. An estimated 346 million of 
people worldwide have diabetes and the number is projected to rise to 360 
million by the year 2030 and approximately 4.5% of the UK population is 
diabetic (Wild et al., 2004). According to the World Health Organization, 
diabetes mellitus is responsible for about 12% of new cases of blindness between 
the ages of 45 and 74 years in the developed world. Diabetic retinopathy (DR) 
is the commonest cause of visual impairment in persons below the age of 65 
years (Hendrick et al., 2015). DR is a frequently occurring complication of 
diabetes, and is a progressive condition with microvascular alterations that lead 
to retinal ischemia, retinal permeability, retinal neovascularization and macular 




Risk Factors DR 
Both the duration of diabetes and glycaemic control are independent risk factors 
for severity and progression of DR. Younger-onset diabetics’ have twice the 
prevalence of advance (proliferative) diabetic retinopathy compared with the 
older-onset group that takes insulin (RCOphth and Ophthalmologists, 2013): 
The prevalence of DR is 48.4% in the population with type 1 diabetes mellitus 
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(T1DM) and 28.3% in the population with type 2 diabetes mellitus (T2DM). 
Among patients with T2DM, severe DR risk increased in South Asian groups 
and more deprived groups. Relative risk of DR for patients with T1DM varied 
by age and region, but not by gender, ethnic group or deprivation (Mathur et al., 
2017). 
 
Classification of DR 
Various DR classification systems have been described in literature. Such 
classifications consist of 2 different approaches. The first is based on the 
presence or absence of new vessels (traditional background [non-proliferative] 
vs proliferative retinopathy, which may be associated with maculopathy. The 
second is based on the presence or absence of centre-involving/subfoveal 
macular oedema and/or ischaemia. These 2 systems are not mutually exclusive. 
 
Diabetic macular oedema (DMO) can be divided in focal and diffuse subtypes. 
Focal DMO is caused by focal leakage of microaneurysms. Diffuse DMO is 
caused by a generalized breakdown of the inner blood/retinal barrier. The Early 
Treatment Diabetic Retinopathy Study (ETDRS) used the proportion of 
microaneurysmsal fluorescein leakage to differentiate focal and diffuse DMO 
conditions. Eyes with ≥ 67% of leakage originating from microaneurysms were 
classified as focal DMO. Eyes with microaneurysmsal leakage between 33% and 
66% were determined to have intermediate DMO. Eyes with ≤33% 
microaneurysmal leakage were classified as having diffuse DMO (ETDRS, 
1995). ETDRS defined clinically significant macular oedema (CSMO) as 
“thickening of the retina at or within 500 μm of the centre of the macula; or hard 
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exudate at or within 500 μm of the centre of the macula associated with 
thickening of adjacent retina; or a zone of retinal thickening 1-disc area or larger, 
anywhere in macula (ETDRS, 1995, ETDRS, 1991b). 
 
Regarding the presence of neovascularisation, DR can be classified as non-
proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy 
(PDR). NPDR is further graded as mild, moderate and severe according to the 
ETDRS severity scale (ETDRS, 1991a). The International Clinical Disease 
Severity Scale for Diabetic Retinopathy defined five severity stages for DR 
(Wilkinson et al., 2003). The first is “no apparent retinopathy”. The second is 
“mild NPDR”. This stage is characterized by the presence of a few 
microaneurysms. The third stage is “moderate NPDR” which is characterized by 
the presence of microaneurysms, intraretinal haemorrhages or venous beading 
that do not reach the severity standard. The fourth is “Severe NPDR”, this 
classification is based on the 4:2:1 rule of the ETDRS, where severe NPDR is 
present if: haemorrhages are present in all 4 quadrants, 2 quadrants or more have 
venous beading, 1 or more quadrant has intraretinal microvascular abnormalities 
(IRMA). The final stage is “proliferative diabetic retinopathy”. PDR is 
characterized by neovascularization of the disc, neovascularization of the retina, 
neovascularization of the iris, neovascularization of the angle, vitreous 
haemorrhage or tractional retinal detachment (Murphy, 1995, Wu et al., 2013a). 
PDR increases risk of vitreous haemorrhage, retinal fibrosis, and tractional 
retinal detachment with significant risk of vision loss. 
 
 




DMO can be assessed evaluating retinal thickness through OCT devices in the 
nine ETDRS subfields. Centre-involving DMO is defined as presence of oedema 
in zone 1 (fovea). Non-centre-involving DMO is related to oedema located in 
one or more of the subfields 2–9. Approximately 8% of people with diabetes 
have centre-involving DMO and a further 8% have non-central DMO. Not all 
patients with centre-involving DMO have impaired vision, therefore progression 
must be measured as an increase in retinal thickness in all nine zones as well as 
total macular volume. Fundus fluorescence angiography (FFA) is of great value 
to detect microvascular damages and retinal ischemia in the early stage of DR. 
It is currently the gold standard for evaluating the retinal vasculature. In FFA 
microaneurysms appear as punctate areas of hyperfluorescence. Patchy areas of 
hypofluorescence can signify ischemia from nonperfused retinal capillaries. An 
increase in the foveal avascular zone from macular ischemia can be seen using 
FA, which may help explain vision loss in some diabetic patients, however 
macular function can only be presumed from FFA images. FFA can also show 
abnormal blood vessels in the eye such as intraretinal microvascular 
abnormalities (IRMA) or retinal neovascularization. The visualization of 
leakage of fluorescein dye over time is useful in showing the breakdown of the 
blood-retinal barrier. Retinal neovascularization also can cause fluorescein 
leakage, and FFA is a useful test to confirm the diagnosis of neovascularization 
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Management of DR 
Diabetic patients can be managed in an appropriate screening programme. 
Patients with PDR and patients with centre-involving macular oedema are 
referred to the hospital eye service for treatment. Other patients with less severe 
retinopathy may be observed with close monitoring. Based on severity signs, 
retinal laser photocoagulation may be considered. Pan-retinal photocoagulation 
(PRP) laser treatment reduces risk of vision loss in PDR. Focal or grid macular 
laser photocoagulation was standard in management of DMO which was non-
ischaemic. Treatment outcomes have improved considerably with the 
introduction of intravitreal therapies to inhibit vascular endothelial growth factor 
(VEGF), which is thought to be the central mediator of neovascularisation in 
these retinal vascular diseases, and inhibitors of inflammation. Intravitreal anti-
VEGF injections can be useful in stabilising PDR although more permanent 
treatment is still reliant on PRP (Alexander et al., 2012). 
 
Patients with non-centre-involving diabetic maculopathy can be treated with 
laser photocoagulation according to modified ETDRS criteria or with 
MicroPulse laser. Patients with centre-involving macular oedema (central 
macular thickness ≥250 μm and visual acuity in the region of 6/10—6/90) would 
benefit most from anti-VEGF (with ranibizumab or aflibercept) treatment, which 
may be combined with laser treatment. Where ranibizumab 
(Genentech/Novartis) or aflibercept (Regeneron/Bayer) is not available, 
bevacizumab (Roche/Genentech) may be considered. Intravitreal steroid therapy 
with dexamethasone implant (Ozurdex, Allergan) or Fluocinolone (Iluvien, 
Alimera) injections offer other potential options. Where these licensed steroids 
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are not available, intravitreal injection of triamcinolone can be considered as an 
alternative option. Patients unsuitable for injections can be offered macular laser 
treatment. If there is evidence of vitreomacular traction, vitrectomy may be 
considered with or without adjunctive anti-VEGF/steroid treatment. Patients 
needing laser treatment require 3-monthly or 4-monthly follow-ups, whereas 
patients undergoing anti-VEGF injections need monthly follow-up, at least in 
the first year. Patients with early maculopathy (no CSMO) and background 
retinopathy can be followed up through colour images and OCT, at 4–6 monthly 
interval (RCOphth and Ophthalmologists, 2013).  
 
 
1.5 Low Vision 
 
Despite recent progress in the treatment of nvAMD, there are currently no 
proven treatments available for dry AMD.  However, fortunately dry AMD 
progresses slowly, and usually spares the central vision till late in the disease. 
As such, only a proportion of dry AMD cases progress up to the point to cause 
legal blindness (Buckle et al., 2015). Instead individuals with moderate to 
advanced dry AMD develop central or paracentral visual field defects 
(scotomas) or  moderately/severe reduced vision, ending up as Low Vision (LV) 
patients.  
 
Patients are categorised as having LV when a significant loss of vision cannot 
be corrected medically, surgically, or with the best possible corrective lenses, 
but which may be improved with special aids or devices. LV may be the result 
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of different ocular pathologies of either congenital disease, such as retinitis 
pigmentosa, or of acquired conditions such as AMD. Subjects with LV 
secondary to maculopathies can only improve their quality of life through vision 
rehabilitation services by learning how to use their remaining vision more 
effectively.   
 
LV patients with central scotoma perform visual tasks with the eccentric parts of 
the retina, which regularly leads to unstable fixation. The size of central scotoma 
has already been established as an important determinant of visual acuity, 
reading capability and reading speed. The rehabilitation process for such LV 
patients typically consists of the use of prisms, magnifiers and other non-
technological aids as mobility training, counselling and education (Klein et al., 
1997). 
 
Some of the visual disturbances related to low vision are (Lamba and Ahmed, 
2016): 
i)       Lower central visual acuity or fluctuating vision. These patients 
initially report the inability to read small print, or that the letters of 
the reading target move constantly. 
 
ii)       Metamorphopsia. People describe a distortion of vision and may 
complain of haze all the time. Objects appear to bulge, curve, or “look 
funny”. 
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iii) Photophobia. Patients either complain of abnormal sensitivity to 
light or do not report the problem but use very dark glasses or avoid 
high levels of illumination. Recovery from glare is slow, and 
adaptation to light is difficult. 
 
iv)       Colour Distortions. Persons with this condition indicate they cannot 
detect colours, or functional observations show they have trouble 
identifying colours. 
 
v)       Field Defects. These patients report they have no vision in specified 
sectors of the visual field; objects disappear to the right, left, and so 
forth, and parts of an object being viewed are always missing. 
Frequently, field loss is detected through functional observations 
rather than from direct reports from the person experiencing it. 
Common losses include: (1) general contraction or depression 
(objects in the periphery are not seen), (2) Hemianopsia (the right 
half, left half, upper or lower half of the visual field is missing), and 
(3) Central Scotoma (in which the macula is no longer functioning 
but all the retina tissue around the scotoma area is intact). 
 
vi)        Night Blindness. Persons who have night blindness indicate a 
decreased ability to see at night and difficulty in performing specific 
tasks at night or are observed to function worse at night. This 
condition can be confirmed by clinical tests such as electrodiagnostic 
examinations. 
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vii)      Entopic Images. Persons with this condition see floaters or spots 
before their eyes, including stationary spots that move with the eye; 
these floaters or spots momentarily interfere with vision. Such 
symptoms may indicate an active pathology, so appropriate care 
should be provided by the staff optometrist or ophthalmologist. 
 
       viii)    Oscillopsia. Persons with oscillopsia report that the world seems to 
be moving or jumping around. This condition may be related to a 
loss of foveal function or a sign of neurological disorder; therefore, 
persons suffering from it should be referred to a neurologist or 
another appropriate physician. 
 
Many of the above described LV conditions provoke involuntary eye movements 
as a reflex of the oculomotor system aiming a visual target during a redefinition 
of a retinal locus which may substitute central vision. Manifestations of 
disordered eye movement include a loss of conjugate movements, broken pursuit 
movements, inaccurate saccades, gaze palsies and nystagmus (Tarita-Nistor et 
al., 2008). 
 
Management of LV 
Patients with central vision loss can benefit from eccentric vision therapy by 
using their remaining vision more effectively. Fixation control is the essential 
part of such therapeutic process. Biofeedback fixation training (BFT) can aid 
patients to learn how to use their best functional eccentric retinal locus, in a 
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totally controlled environment, with the scope to convey newly acquired 
oculomotor skills into daily living improving quality of life. BFT is a 
technological aid used in the rehabilitation process for low vision patients with 
eccentric and unstable fixation. This technique is based in the theory of Brain 
Plasticity where areas of residual vision can be identified and repetitively 
stimulated, improving the ocular motor control. 
 
BFT rehabilitation consists of asking patients to move their gaze toward a pre-
selected direction related to a specific retinal zone with good light sensitivity 
(Nilsson et al., 1998); the gaze movement is accompanied by an intermittent 
beep sound which increases its frequency whilst it approaches the selected area. 
When the eye movement hits the target the beep sound becomes constant whilst 
visual stimuli are presented. The combination of visual stimuli and audio 
feedback helps patients develop a better functional residual vision (Tarita-Nistor 
et al., 2009b). 
 
The incorporation of BFT in MP devices adds the advantage of the anatomico-
functional analysis, whereas MP maps out precisely areas of good retinal 
sensitivity over a fundus image, that may be used for eccentric vision. 
Unfortunately, to date, there are no standardised methods for eccentric vision 
training with MP and biofeedback. 
 
  









Standard Automated Perimetry (SAP) 
Standard automated perimetry (SAP) is a well-known method of measuring the 
field of view. This visual field analysis, examines light threshold sensitivity 
(LTS) of different spatial locations of the retina. The function of perimetry is to 
indicate the site and the extent of involvement of the visual pathway. It is a 
standard examination in glaucoma management, where monitoring of LTS 
progression of the peripheral retina is an integral part of the glaucoma evaluation. 
However, such tests may not be reliable in macular pathologies due to patients’ 
inability to hold their fixation during the long perimetry testing, particularly in 
those cases when central vision is affected. 
 
The Humphrey Visual Field Analyzer (HFA) is the most commonly used SAP. 
Visual field analysers have standardized quantitative results on SAP instruments 
through practical statistical methods to measure early functional loss in 
glaucoma. The high sensitivity of the methods has required attention to the 
multiple psychological and physiologic variables that may affect measured 
thresholds. Although SAP has reduced variability in the examination technique, 
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the test still depends on the reliability of the patient’s responses, the ability to 
see the instrument’s fixation target, and may be affected by optic, neural, and 
psychological factors.  
Although detailed measurements of the visual field can be obtained, 
differentiating long-term fluctuation from progressive loss remains one of the 
greatest clinical challenges in visual field interpretation (Wong and Plant, 2015). 
 
To map the visual field, perimetry measures the differential LTS of a stimulus 
projected at multiple locations in different retinal loci, with variable luminance 
against a constant illuminated background. Currently, the standard SAP test is a 
Goldmann size III stimulus, a white circular projection, whose diameter is 0.43° 
of visual angle. However, other stimulus sizes can be used (Swanson, 2013). The 
highest limitation of perimetry testing is subjectivity, as patients are asked to 
press a response button once the stimulus is seen. 
 
Visual field test in SAP can be either static or dynamic. In static perimetry, 
sensitivity thresholds are determined at specific locations of the visual field. 
These thresholds are then compared to those of normal controls. Small changes 
in LTS can be detected with accuracy; however, this is highly dependent on 
patient’s ability to hold their gaze steady on the fixation target for a long period 
of time. Probably, the major limitation of static perimetry is that, examination 
time depends on the number of stimuli projected, as this increases patient’s 
fatigue, reducing the ability to fixate. Therefore, a compromise between stimuli 
separation and visual field coverage must be achieved, resulting on a low spatial 
resolution test. For such reason, static perimetry is typically limited to the central 
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30° of the visual field. Conversely, kinetic perimetry, provides higher spatial 
resolution and is faster for peripheral testing. However, it involves greater 
interaction between the patient and the examiner. In kinetic perimetry, sensitivity 
thresholds are determined by moving stimuli of various sizes and luminosities 
from a region of non-seeing to a region of seeing.  
 
Perimetry outcomes are a grayscale representation of the visual field map with 
numeric readouts in decibels which indicate the location and density of visual 
defects, where the non-seeing regions are defined as scotoma.  
 
The biggest limitation of perimetry testing in patients with macular pathologies, 
is the assumption that, the point of fixation is the fovea, and that patients are able 
to hold their fixation steady during the whole examination time, which is not the 
case of patients with central vision loss secondary to macular pathologies. 
 
Microperimetry (MP) 
Microperimetry (MP) is also known as Fundus-related perimetry. Today MP is 
a well-known instrument in studying retinal functional characteristics, such as 
light threshold sensitivity (LTS) and patient’s fixation capacities. It was firstly 
reported by Sunnes et al. (Sunness et al., 1995) as a Scanning Laser 
Ophthalmoscope (SLO) perimetry, a perimetry test that, with the aid of an eye 
tracker, based on retinal landmarks, compensates for eye movements during 
testing, therefore, the correct retinal location is tested, even if fixation changes, 
allowing for accurate testing of patients with central scotomas and for repeating 
testing longitudinally at the same retinal locations even if central fixation is lost. 
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Sunnes studied, for the first time, fixation behaviour and reading rates in patients 
with central scotoma with the SLO perimetry (Sunness et al., 1996). 
Rohrschneider et al., correlated reading capacities with the SLO fundus 
perimetry and later proposed that the analysis of functional outcomes with SLO 
perimetry was a better predictor of visual function after laser photocoagulation 
treatment (Rohrschneider et al., 1996, Rohrschneider et al., 1997). However, 
such SLO perimetry was barely used as a consequence of its high cost, and a 
lack of automatism and standardization of the visual field test. 
 
The automated MP test is a fundus related perimetry with similar functional 
characteristics as those to the SAP or visual field test, where patients are asked 
to look at the centre of a fixation target whilst, points of white light are 
automatically projected several times at different light intensities over different 
parts of the retina. The stimuli grid distribution and projection strategy are 
equivalent to those of a basic field analyser. Patients are asked to press a response 
button when they perceive the light stimulus, thus a LTS map is created.  
 
The disadvantage of MP compared to SAP is that, the retinal area covered by the 
test is reduced to less than 45 degrees on account of the fundus image size 
limitations. For that reason, MP examinations  have been limited to the analysis 
of the central retina as initially reported by Midena et al., who described MP as 
a reliable technique to analyse detailed macular function in AMD patients, 
exalting the advantage of topographic correlations between macular anatomy 
and LTS (Midena et al., 2004). In essence, the main difference with SAP is that, 
MP is a fundus imaging device which controls eye movements through a retinal 
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landmark eye tracker, such that retinal LTS outcomes are fundus correlated. In 
addition, microperimetry assesses fixation characteristics such as fixation 
stability and the area of the retina used during fixation attempts, also known as 
the preferred retinal locus (Von Noorden and Mackensen, 1962, Fletcher and 
Schuchard, 1997). 
 
In 2003, Nidek Technologies (Padova, Italy) introduced the first automated MP, 
the MP-1. It was first reported by Midena et al., in a study that analysed macular 
function in patients with subfoveal CNV secondary to AMD (Midena et al., 
2004). In that study, Midena evoked MP as an instrument to quantify in detail 
(better than visual acuity), the effects on macular function of subfoveal CNV 
treatments. The value of MP evaluation in AMD and other macular diseases is 
that, light threshold assessments are independent of patients’ capabilities to hold 
their fixation during the examination, particularly in patients with foveal 
involvement. The fundus correlation allows precise follow up for comparisons 
of sequential examination.  
 
The MP-1 produces a 45° field of view fundus image in real time on a video 
monitor using an infrared (IR) fundus camera with an image resolution of 768 x 
576 pixels and a 25Hz eye tracker that samples the eye movement by following 
2 retina landmarks selected at the beginning of the procedure. Fixation target and 
stimuli are projected on a liquid crystal colour monitor. Adopting the perimetric 
standard of the Octopus automated perimeter, the MP-1 background illumination 
was set on 4 apostilb (asb), equivalent to 1.27 candles/square meter. The 
brightest stimuli luminance, which was limited by the colour monitor, was 400 
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asb (127 candles/square meter), allowing a stimulus dynamic range from 0 to 20 
decibels (dB).  
 
The MAIA MP 
The Macular Integrity Assessment (MAIA) system (Centervue S.p.A, Padova, 
Italy), is the 3rd MP generation. It improved the limitations of the previous 
technologies with an easy to use instrument and lower price. The MAIA 
combined the advantage of a high-resolution retinal imaging system using a SLO 
technology (1024 x 1024 pixels) and a more effective eye tracker which 
automatically tracks the whole retina image and not only 2 landmarks as in the 
case of the MP-1. This improved the reliability and usability of the MAIA for 
operators and patients, as described by Vujosevic et al (Vujosevic et al., 2010a). 
The eye tracker speed for both technologies is 25Hz, as it is the maximum 
effective frame rate in synchrony with the imaging technology. The MAIA 
maximum stimulus luminance is 1000 asb, whilst the stimulus dynamic range is 
36 dB compared to the maximum luminosity of 400 asb and 20 dB dynamic 
range of the MP-1. Vujosevic reported the MAIA average LTS outcomes 
compared to a normal reference database (Vujosevic et al., 2010a). 
 
The MAIA manufacturer conducted an internal sponsored study with the 
purpose of establishing a normative, age-related database on LTS, and fixation 
stability for the MAIA in normal, early-stage AMD, and intermediate-stage 
AMD eyes. The results served to generate an algorithm that differentiates normal 
eyes from those with early- and intermediate-stage of AMD.  
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The study included 494 eyes from 265 subjects with normal visual conditions, 
200 eyes with classified early-stage AMD, and 155 eyes classified with 
intermediate AMD. Both eyes were analysed for normal participants, whilst only 
one eye was analysed for each patient with AMD. The analysed data was, the 
mean LTS, fixation stability and fixation location. Age range was from 21 to 86 
years of age. Outcomes were analysed in five age groups. Group 1 included 
patients from 20 to 29 years, group 2 from 30 to 39, group 3 from 40 to 49, group 
4 from 50 to 59 and group 5 was composed for participants with more than 60 
years of age. 
 
A Goldmann III stimuli grid of 61 stimuli distributed in 5 rings separated at 
1° was used (Figure 2.1). The projection threshold algorithm was the standard 
full 4-2 staircase. 
 
Stimuli grid used to establish the normative database for the 




Figure 2.1  MAIA normative grid 
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A linear regression was used to compute mean LTS and participant’s age on 




A significant decrease in retinal LTS was found in AMD patients compared to 
normal, while FS showed a reduction between normal and AMD, patients, but 
the reduction among AMD stages was not significant, as shown on Table 2.1. 
 
Table 2.1  MAIA normative values 
 Normal AMD 2 AMD3 
Sensitivity (dB) 29.78±1.71 24.85±3.87 21.76±5.36 
P1 88.79±15.18 79.09±24.88 77.46±26.83 
P2 97.05±6.18) 91.5±16.92 89.85±20.55 
 
Summary statistics for mean light threshold sensitivity and fixation stability for all groups. 
Values are expressed in the mean ± SD. P1: percentage of points having distance less than 1° 
from the centre of mass of all fixation points. P2: percentage of points having distance less than 
2° from the centre of mass of all fixation points. 
 
Figure 2.2  MAIA normative data 
Means (blue) and standard deviations (yellow) in dB of threshold values for 
normal eyes vs. age. Linear regression line and equations are shown (N = 494). 
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Spatial variability of LTS was assessed as the mean value for all points located 
at each ring, and showed significant changes between groups 1 (age 20-29), 4 
(age 50-59) and 5 (age 60+), as shown in Table 2.2. 
 
 
Table 2.2  Normative group results 
 
Mean light threshold sensitivity of each stimuli ring for age groups 1, 4 and 5. 
 
The normative study concluded that macular sensitivity is reduced in patients 
with early and intermediate AMD when compared to age-matched normals. LTS 
reduction is more relevant in intermediate than in early AMD. Fixation is altered 
in AMD patients when compared to normal subjects.  Fixation does not differ 
significantly between AMD 2 and AMD 3 groups. Therefore, the macular MP 
test may be useful in early diagnosis of AMD, mainly in the screening 
setting.(Vujosevic et al., 2010b). 
 
Scotopic Microperimetry 
Standard microperimetry is considered a mesopic examination. The test is 
performed under dim light conditions (mesopic) as LTS of the retina is assessed 
with achromatic (white) stimuli, which stimulate both cones and rods 
photoreceptors. However clinical studies have shown that in some degenerative 
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retinal diseases the sensitivity of the rods and cones may change asynchronously 
(Nebbioso et al., 2014). Therefore, there was an intrinsic need to study 
independent function of cones and rods. Scotopic microperimetry fulfils this 
need by performing LTS under dark adaptation. The scotopic MAIA system (S-
MAIA) is equipped with two different chromatic stimuli, cyan (505 nm) and red 
(627 nm), so that cones and rods mediation can be studied independently under 
scotopic conditions. The cyan testing is intended to be largely derived from rod 
photoreceptor-mediated function, whilst the scotopic red would be more 
influenced by cone-mediated function (Pfau et al., 2017a). 
 
More recently, the microperimeter MP-3 (Nidek Co, Japan) became available. 
The technology is similar to the one in the MP-1, with an infrared imaging 
system used during testing for motion capturing. In contrast to previous 
devices, the eye tracking frame rate is 30 Hz, the background luminance is set 
at 31.4 asb, whilst the maximum luminance is 10,000 asb, with a stimuli 
dynamic range of 34 dB. However, such device was not available at the time 
when the present investigation took place. 
 
Preferred Retinal Locus 
The anatomical area of the retina used to fixate is known as Preferred Retinal 
Locus (PRL). The PRL in microperimetry is defined by the cloud of fixation 
points distribution, superimposed over the fundus image. The PRL in healthy 
retinal conditions is centrally located on the fovea, whilst  in patients with central 
vision loss it is located eccentrically commonly associated with unstable fixation 
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(Sullivan et al., 2008). In general, the more peripheral the PRL is located, the 
more unstable the fixation becomes (Morales et al., 2013). 
 
Fixation Stability 
Patients’ fixation characteristics in MP are determined by sampling the position 
of a reference fundus image at the eye tracker speed (25 Hz). The centre of each 
sampled frame is superimposed on the initial reference image creating a cloud 
of fixation points. The location and distribution of such points are used to 
determine fixation stability (FS) and the PRL. MP systems currently use two 
different approaches to measure FS. The first FS measurement method calculates 
the percentage of fixation points falling inside a circle of 1° and  2° radii (defined 
in the MAIA MP as P1 and P2, respectively) centred on the barycenter of the 
cloud of fixation points (Morales et al., 2013). The main advantage of this 
method is the clinical classification of FS as suggested by Fujii et al., where eyes 
with P1 greater than 75% are classified as having stable fixation; if P1 is less 
than 75% and P2 is more than 75%, fixation is classified as relatively unstable; 
and if both P1 and P2 are less than 75%, the pattern is described as unstable 
fixation (Fujii et al., 2002). This methodology has been criticized in the literature 
because of the arbitrarily selected parameters of the distances of 1° and 2° used 
to establish such FS index.  
The second FS measurement method suggested by Crossland et al., is known as 
the bivariate contour ellipse area (BCEA) (Crossland et al., 2009). It calculates 
the area and orientation of an ellipse encompassing a given proportion (ρ) of the 
fixation points’ dataset. This is a two-dimensional elliptical representation that 
describes the limits of the retinal surface area used during a fixation attempt, 
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where lower BCEA values define better fixation stability (Crossland et al., 2009, 
Crossland et al., 2004, Crossland and Rubin, 2002). The advantage of the BCEA 
calculation over the percentage of fixation points is that it is based on a 
mathematical model used in statistics to describe movement of variables. 
However, it is not related to any clinical classification in MP. 
 
Biofeedback Fixation Training 
When central vision loss results from macular degeneration or retinal 
dystrophies affecting the fovea, fixation becomes unstable. In such cases, MP is 
useful in mapping out, with precision, the vision loss zone and determining LTS 
on different areas of the eccentric retina. This analysis is useful in determining 
the best functional eccentric locus that may be used by patients with loss of 
foveal vision when attempting visual tasks. 
 
Automatic MP includes biofeedback technology which has the scope to improve 
eccentric vision capabilities by improving fixation stability in patients with 
central vision loss. Through oculo-motor training, patients are instructed to use 
their best potential eccentric retina, by moving their gaze in a way that a visual 
target falls on the healthier eccentric locus. With several sessions, patients may 
learn to use their residual vision more effectively (Markowitz, 2006). 
 
 Biofeedback fixation training is, therefore, a technological aid used in the 
rehabilitation process for LV patients with eccentric and unstable fixation. This 
technique is based on the theory of Brain Plasticity (Markowitz, 2006), where 
areas of residual vision can be identified and stimulated, improving the ocular 
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motor control for better residual visual performance. Unfortunately, this 
technique is not well known, and there are no standardised methods for such 
rehabilitation method.  
 
Clinical Review on Microperimetry 
It has been reported that MP may provide insight into the changes in macular 
function after retinal pigment epithelial (RPE) transplantation, macular thickness 
changes in diabetic retinopathy, anti-VEGF therapies in AMD, and retinal vein 
occlusion (Winterhalter et al., 2012). Karacorlu et al found that intravitreal 
bevacizumab (Genentech, Inc., South San Francisco, CA, USA) therapy in 
previously untreated patients induced a significant increase in mean retinal LTS 
and a reduction in mean scotoma size (Karacorlu et al., 2010). Hatef et al., 
showed that in eyes with diabetic macular oedema, with a retinal thickness value 
of 280m or less at the fovea,  retinal thinning was associated with decreased 
retinal sensitivity (Hatef et al., 2011). Landa et al., suggested that retinal 
sensitivity was correlated with the status of the underlying IS-OS junctional 
layer in both dry and wet forms of AMD (Landa et al., 2011). 
 
Alexander et al., reported the relationship between macular sensitivity, central 
retinal thickness and visual acuity in the maintenance phase of ranibizumab 
therapy using the MAIA microperimetry.  Some patients with stable visual 
acuity and central retina thickness were shown to have deteriorating retinal 
sensitivity, which may indicate subclinical disease activity (Alexander et al., 
2012), while Ozdemir et al., reported reduction in mean scotoma size with 
intravitreal bevacizumab therapy (Ozdemir et al., 2012). 
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Recently, in a report from the NEI/FDA workshop on age-related macular 
degeneration and inherited retinal diseases, MP was acknowledged as an 
instrument for generating retinal sensitivity maps. Jaffe has suggested that the 
OCT (anatomical) and microperimetry (functional) correlation may be a suitable 
functional outcome measure for progression in Stargardt disease. However, 
Chambers reported that in certain areas of the retina, particularly in the ellipsoid 
zone at the edge of the lesion, the correlation between microperimetry and OCT 
data is not perfect; however, if the extent of change is outside the ‘questionable 
area’, then this parameter is likely to be acceptable as a surrogate endpoint for 
such retinal pathologies (Csaky et al., 2017). 
 
 
2.2 The Topcon Optical Coherence Tomography 
(OCT) 
 
Optical coherence tomography (OCT) is one of the most successful imaging 
technologies implemented in the ophthalmology practice. It is based on low-
coherence interferometry, used in the diagnose and monitoring of retinal 
pathologies capturing two- and three-dimensional structural images of the retina. 
OCT is analogous to ultrasound imaging, where a sound pulse is launched and 
the reflections (echoes) are measured to create an image of tissue. In OCT light 
reflections are measured by a Michelson interferometer, using the low coherence 
properties of a broadband light source. By measuring this interference, the 
location and strength of the reflections can be determined. There are in essence 
two types of OCT technology according to their evolution: Time Domain (TD-
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OCT) and Fourier Domain (FD-OCT), which can in principle be performed in 
two ways: either by using a spectrometer, commonly named Spectral Domain 
OCT (SD-OCT), or by using a fast tuneable laser, called Swept Source OCT 
(SS-OCT). Both approaches have in common that the reflectivity is measured 
for a multitude of wavelengths separately. By combining the information of 
those wavelengths, a depth profile with high resolution can be created (de Boer 
et al., 2017). OCT has been established as the “Gold Standard” for the diagnosis 
of ocular pathologies. However, since it is a diagnostic technique based 
exclusively on the structural image, it does not offer by itself the possibility of 
evaluating functional data regarding visual function. Nowadays with the 
emergence of Anti-VEGF treatments, OCT has fulfilled the need for a precise 
and exhaustive follow-up of patients, in virtually all ophthalmological practices 
as routine tests. The Topcon SD-OCT (Tokyo, Japan) is able to produce up to 
85000 A-Scans for up to 256 parallel B-Scans, creating structural retinal images 
with resolution that reaches 5 microns, whilst the B-Scan length goes from 6 mm 
to 12 mm. 
 
 
2.3 International Reading Speed Test (IReST). 
 
Visual acuity is normally assessed by the Snellen or the ETDRS charts. These 
are a reliable visual performance assessment in cases of patients with functional 
foveal. They represent the ability to distinguish one single letter as a visual task. 
However, they are often poor predictors of everyday visual function such as 
reading, especially in cases of patients with central scotoma (Ahn et al., 1995).  
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Different reading texts have been developed to assess visual performance in 
clinical trials. Reading performance analysis may serve as a useful tool in such 
situations because the evaluation of reading speed and reading acuity is easy to 
perform and provides a large amount of information that can easily be 
interpreted. Texts with single sentences for measuring reading acuity, reading 
speed, and critical print size are available, such as MN Read or Radner’s charts. 
The Minnesota Low-vision Reading Text (MN- READ) uses simple sentences 
and common vocabulary to minimize cognitive and linguistic demands. 
Sentences are presented at high magnification so that subjects with low vision 
do not need to manipulate magnifiers. The Radner reading charts use sentences, 
in German language, developed to be comparable in number and length of 
words, as well as in difficulty and construction, with the purpose to offer a 
reliable and valid test for measuring reading acuity and speed (Radner et al., 
2002). 
 
However, for measuring reading speed, a whole paragraph of text is preferable 
to single sentences, because the percentage error of reading time measurements 
in seconds is smaller for longer texts. Furthermore, reading whole paragraphs is 
closer to the demands of everyday reading. The International Reading Speed 
Text (IReST) was created with the purpose to standardized reading performance 
texts through multiple equivalent texts for repeated measurements, and for texts 
equated across languages for multi-language studies. Ten paragraphs of German 
text were designed by a linguist from material for sixth grade reading (age 10–
12 years) with a mean length of 132 words (SD 6 3.2). They were matched for 
difficulty and linguistic/syntactic complexity. The texts were translated into 16 
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languages, and adapted by linguists of the respective language, to be similar in 
number of words, character counts, difficulty and complexity to the German 
original (Trauzettel-Klosinski and Dietz, 2012). 
 
A study to established normal reading speed test parameters was performed with 
436 normally-sighted subjects, who were native speakers of the respective 
languages. Participants were 18 to 35 years of age with normal or corrected-to-
normal vision. The texts were printed and presented in black on white paper at a 
viewing distance of 40 cm and a size of 1 M (5 minutes of arc at 1 m), or 10-
point Times New Roman font, which corresponds to many newspapers print 
sizes. The paragraphs had a maximum line length of 8.5 to 10.0 cm. The mean 
number of lines/text was 14.3. The texts were read aloud. A stopwatch was used 
to measure reading time. Words read incorrectly or omitted were counted. 
Reading speeds was assessed in four different ways: texts/min, words/min, 
syllables/min, and characters (without spaces and punctuation marks)/min. 
Means and SDs were computed for each language using these four measures of 
reading speed. 
 
The MN Read and Radner texts use short and simple (second and third grade 
material) single sentences in different print sizes to assess reading acuity, critical 
print size, and magnification need. Variability among participants depends on 
reading habits and skills. However, within one individual reader the variability 
is relatively low.  
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The IReST differs from prior text charts that used single sentences by employing 
linguistically standardized paragraphs. The IReST instead, due to lower 
variance, measuring reading time of a complete paragraph rather than a single 
sentence or random words is more reliable. Furthermore, it can provide some 
information about fluency, fatigue, and mistakes.(Trauzettel-Klosinski and 
Dietz, 2012) In patients with low vision and central scotoma, it is suggested to 











As summarised in the Aims and Objectives section, this study is divided in 2 
projects: a) Microperimetry in the monitoring of common macular diseases, and 
b) Eccentric fixation training for visual rehabilitation with MP biofeedback 
technology.  
 
The main research question for both projects are: 
 
Project A.  
Is Microperimetry (MP) technology able to provide relevant information 
regarding macular function, to such extent that MP examinations can be 
recommended as an integral part of the standard of care in the management of 
macular diseases? 
 
The National Institute for Health and Care Excellence (NICE) recommendations 
in the managing of age-related macular degeneration include: fundus 
examination to people presenting changes in vision, slit-lamp fundus 
biomicroscopy to confirm diagnosis of early or late dry-AMD, OCT in people 
with suspected late wet-AMD, and FFA to confirm the late wet-AMD diagnosis 
if OCT does not exclude neovascular disease. During the treatment and 
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monitoring phase of late wet-AMD, NICE recommends ongoing monitoring 
with OCT for both eyes, and fundus examination or colour photography if OCT 
appearances are stable but there is a decline in visual acuity, or the person reports 
a decline in visual function. If OCT results suggest macular abnormalities but 
the abnormalities are not responding to treatment, the NICE guidelines suggest 
to use “alternative imaging” (NICE, 2018). However, up to date functional 
retinal examinations, such as MP, have not been considered in the management 
of AMD at any stage. 
 
Project B.  
Is the eccentric fixation training performed with MP technology an effective 
rehabilitation proposal, which can improve vision in people with central vision 
loss secondary to macular pathologies? 
 
The NICE guidelines suggests referring to low-vision services, people with 
visual impairment secondary to late AMD, and consideration of eccentric 
viewing (EV) training for people with central vision loss in both eyes (NICE, 
2018). EV is an adaptive strategy used to compensate for central vision loss in 
which relatively healthy paracentral areas of the retina are used to fixate objects. 
People are taught to use a specific paracentral area of retina during EV training, 
known as the trained retinal locus (TRL). However, there is insufficient evidence 
to conclude that a particular model of EV training is effective, and there are no 
robust studies aimed to optimise or standardised EV training techniques 
(Gaffney et al., 2014). 
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3.1 Study design and protocol Project A 
 
This was a longitudinal observational, non-randomized, prospective cohort study 
in patients with treatable macular diseases, to determine the utility of the MAIA 
MP in monitoring intravitreal treatment outcomes. 
 
Patients from the Macular Clinic of the Nottingham’s Queen Medical Centre, 
scheduled for treatment with anti-VGEF intravitreal injections of one or both 
eyes for wet AMD or DMO secondary to retinal vein occlusions (RVO) were 
invited to participate in the study. All patients had a routine clinical evaluation 
including, best corrected visual acuity, according to the ETDRS standard, slit 
lamp biomicroscopy of the anterior and posterior segments, and optical 
coherence tomography (OCT). In addition, a fully automatic MAIA 
microperimeter (MP) examination was performed to study macular function 
outputs of retinal light threshold sensitivity and fixation stability. The 
appropriate intravitreal therapy with ranibizumab or bevacizumab for wet AMD, 
or DMO, and ranibizumab or dexamethasone implant for RVO was administered 
as clinically necessary, as recommended by the Royal College of 
Ophthalmologists guidelines.  
 
All examinations were performed at base-line, before any clinical or surgical 
intervention, and repeated on follow-up visits at 3 months, 6 months, and 12 
months from baseline. 
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Study treatment and regimen 
All participants were involved for 12 months after enrolment, and performed the 
following tests at baseline, 3, 6, and 12 months 
-Best corrected Visual Acuity measure (EDTRS), 
-OCT at baseline, 
-MAIA MP with the standard macular grid automatically centred on the patient’s 
PRL. 
-Fluorescein angiography when clinically indicated. 
 
The MAIA examination was performed over the 10° diameter central retinal 
area, using the standard macular grid (37 measuring points) with automatic grid 
centring on the patient’s preferred retinal locus (PRL). The MP follow-up test 
was automatically performed over the same anatomical area tested during the 
baseline examination. 
 
Primary and secondary endpoints 
The primary endpoint was the quantitative analysis of the MP functional outputs 
of retina sensitivity, fixation stability and fixation location during the assessment 
of macular therapy correlated to OCT and visual acuity.  
 
The secondary endpoint was a qualitative evaluation regarding the capacity to 
understand better patient’s visual conditions from the MP outputs correlated to 
OCT outputs and visual acuity.  
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Recruitment 
Participants were recruited from the Medical Retina and Macular clinic of the 
Nottingham’s Queen’s Medical Centre. The initial approach was from a member 
of the patient’s usual care team which may include the investigator. The 
investigator or a member of the research team, informed the participant all 
aspects pertaining to participation in the study.  
 
Inclusion and exclusion criteria 
Inclusion Criteria: 
• Signed Informed consent. 
• No limitation to race, sex or ethnicity. 
• Adult age above 21 years old. 
• Visual acuity LogMAR 0.2 to 1.2. 
Newly diagnosed patients with: 
• Choroidal neovascularization – AMD and non-AMD. 
• Retinal vein occlusion (central [CRVO] or branch [BRVO]) with or without 
MO. 
• Diabetic macular oedema (DMO). 
• Patients with other macular pathology (Central serous retinopathy [CSR], 
Macular hole [MH], epiretinal membrane [ERM]), included as untreated 
controls. 
• OCT presence of macular oedema. 
• Patients willing to attend for follow-up microperimetry examinations. 
• Planned treatment with intravitreal dexamethasone (Ozurdex), ranibizumab, 
bevacizumab, and/or laser photocoagulation. 
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• Concomitant treatment, such as appropriate intravitreal therapy with 
ranibizumab or bevacizumab for AMD, or DMO, and ranibizumab or 
dexamethasone implant for RVO. 
 
Exclusion criteria: 
• Moderate to severe cataract (over grade 2) or other cause of opaque optical 
media. 
• Previous treatments in the particular eye with intravitreal therapies of anti-
VEGFs or steroids within the previous 6 months, or macular laser 
photocoagulation 
• Uncooperative patient. 
• Previous vascular event in the eye of interest other than current diagnosis. 
 
3.2 Study design and protocol Project B 
 
This was a pilot, longitudinal, observational, prospective cohort, non-
comparative, non-randomized, interventional study, on low vision patients with 
central vision loss secondary to late stage maculopathies, to study visual 
improvement after eccentric fixation training with MP biofeedback technology. 
 
Patients from the Macula and Low Vision Clinics of the Nottingham’s Queen 
Medical Centre, diagnosed with low vision secondary to late maculopathies, 
such as, geographic atrophy secondary to late-stage dry AMD, vitelliform 
dystrophy, or central serous retinopathy, scheduled for regular control visit were 
invited to participate in the study. 
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All patients had a routine clinical evaluation including, best corrected visual 
acuity, according to the ETDRS standard; slit lamp biomicroscopy of the anterior 
and posterior segments, and optical coherence tomography (OCT). In addition, 
a fully automatic MAIA microperimeter examination was performed to study 
retinal light threshold sensitivity and fixation stability with the purpose to 
perform eccentric fixation training with the MAIA biofeedback technology. The 
biofeedback fixation training sessions were scheduled on a weekly base during 
12 weeks. After 3 months of resting time, a new set 12 weeks of BFT sessions 
was scheduled. 
 
Study treatment and regimen 
All participants had 2 periods of weekly BFT sessions. Each period lasted 12 
weeks and each session lasted 10 minutes. A 3 months resting time between 
periods was scheduled.  
 
At baseline and at the end of the BFT sessions the following tests were 
performed. 
-Best corrected Visual Acuity (EDTRS). 
-OCT. 
-Reading speed with the International Reading Speed Text (IReST). Different 
text paragraphs were chosen for baseline and for the end of BFT sessions. 
-MAIA MP with the standard macular grid automatically centred on the patient’s 
PRL. 
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In addition, BFT was performed at baseline with the purpose of identifying the 
eccentric retinal location to be used to perform BFT. The following MAIA 
examinations were performed in this regard: A) the “Low-Vision-Assessment” 
grid-test (30°, 83 stimuli) with the 4-levels-fixed projection strategy, which 
scores retinal sensitivity as “good” (25dB), “relatively good” (15dB), “relatively 
poor” (5dB), “poor” (0dB) and “scotoma” (<0 dB); and B) the “Fixation-
Training-Target” grid-test (7°x5°, 35 stimuli) with the 4-2 projection strategy. 
The first test, (A), was centred on the estimated foveal location, or on the 
patient’s PRL in cases of Geographic Atrophy larger than 3 times the optic nerve 
head size. The Low-Vision-Assessment grid output was used to identify retinal 
loci with at least 2 consecutive stimuli, distributed horizontally, showing “good” 
or “relatively-good” light sensitivity, and served as a reference to centre the 
Fixation-Training-Target grid, prioritizing the superior retina (inferior visual 
field) and the smaller distance from the anatomical fovea. The second custom 
test, (B), was used to select the target locus for BFT. This locus was set in the 
centre of the two adjacent stimuli with highest light sensitivity, and lowest 
distance from both the anatomical fovea and the patient’s baseline PRL. 
 
BFT consisted of asking patients to slightly move their gaze towards the training 
locus. An auditory signal increased frequency as the desired eye movement 
reached the target. The microperimeter operator helps the patient with voice 
commands suggesting the direction of eye movements. 
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Primary and secondary endpoints 
The primary endpoint was classification of FS, the MAIA fixation stability 
indices, visual acuity, and reading speed (IReST). The secondary endpoint was 
mean light sensitivity, the anatomical location and the visual field 
correspondence of the PRL. 
 
Recruitment 
The initial approach was from a member of the patient’s usual care team which 
included the investigator. 
The investigator or their nominee, e.g. from the research team or a member of 
the participant’s usual care team, informed the participant or their nominated 
representative (other individual or other body with appropriate jurisdiction), of 
all aspects pertaining to the participation in the study.  
 
Inclusion and exclusion criteria 
Inclusion criteria: 
• Signed Informed consent. 
• No limitation to race, sex or ethnicity. 
• Visual acuity LogMAR 0.4, to LogMAR 2.0. 
• Adult age above 21 and below 80 years old. 
• All patients categorized as eccentric viewers, geographic atrophy area with 
scotoma larger than 1 disk size and smaller than 5 disk sizes.  
• Stable pathology. 
• At least 6 months from last anti-VEGF injection if any. 
• Patients willing to improve reading abilities (based on questionnaire). 




• Mild to severe cataract (over grade 2) or other opaque optical media. 
• Macular Oedema. 
• Uncooperative patient. 
• Non-English speakers. 





Spearman’s rank-order coefficient (rs) and a one-tailed Mann-Whitney test was 
applied to compare baseline and final outcomes, with a significant difference of 
P < 0.05. Linear modelling techniques, paired t-tests (two-tailed) and 
multivariate analysis were also conducted to assess improvement in reading 
speed and VA. 
 
As there are no previous sizeable studies of this kind, it was estimated that an 
appropriate minimum sample size of 100 participants for each project was 
needed to obtain statistical significance results. Data from participants 
withdrawn from the trial prematurely was included in the final analysis up to the 
point of withdrawal.  
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3.4 Ethical and regulatory aspects 
 
Ethics committee  
The trial initiated only after the protocol, informed consent forms and participant 
information sheets received approval of favourable opinion from the Nottingham 
Research Ethics Committee (REC), and the University of Nottingham’s 
Research & Development (R&D) department. The trial was conducted in 
accordance with the ethical principles that have their origin in the Declaration of 
Helsinki, 1996, the principles of Good Clinical Practice (GCP), and the 
Department of Health Research Governance Framework for Health and Social 
care, 2005. All participants provided written informed consent.  
 
Informed consent 
The decision regarding participation in the study was entirely voluntary. Both, 
the investigator and the participant signed the informed consent form before 
undergoing any interventions (including physical examination and history 
taking) related to the study. The investigator emphasized that consent regarding 
study participation could be withdrawn at any time without penalty or affecting 
the quality or quantity of their future medical care, or loss of benefits to which 
the participant is otherwise entitled. The Investigator explained the details of the 
trial and provided a Participant Information Sheet, ensuring that the participant 
had sufficient time to consider participating or not.  
  




4.Clinical Reference Database for 





As described earlier, MP allows an automated analysis of macular function even 
with unstable fixation, as in the case of central geographic atrophy secondary to 
dry AMD. Such assessments are independent of the quality of fixation and eye 
movements. Fixation stability (FS) in microperimetry can be quantified with 
different indices. One of them is the Bivariate Contour ellipse Area (BCEA). 
This chapter is related to a published study that we have conducted reporting a 
reference clinical database for fixation stability metrics of the fixation index 
BCEA in normal subjects measured with the MAIA MP (Morales et al., 2016). 
 
FS is an objective test performed in MP by means of retinal landmark tracking 
which plots the scatter of a cloud of fixation points (CFP) over a retinal image 
reference map. The resulting scatter pattern can then be analysed 
mathematically. 
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Two different approaches have been used in MP to measure FS. The first one is 
related to the quantification of fixation points falling inside a circle of 1° and 2° 
radii, defined in the MAIA as P1 and P2 respectively (Morales et al., 2013). This 
method is used to classify FS in ‘Stable’, ‘Relatively Unstable’ and ‘Unstable’, 
as described in chapter 2 (Fujii et al., 2002). However, such classification has 
been largely criticized in the literature due to the arbitrarily selected distance of 
1° and 2° used to establish such stability index.  
 
The second FS measurement method is known as the bivariate contour ellipse 
area (BCEA). It calculates the area and orientation of an ellipse encompassing a 
given proportion ( ρ ) of the fixation points dataset. This is a two-dimensional 
elliptical representation that describes the limits of the retinal surface area used 
during a fixation attempt, and where lower BCEA values define better fixation 
stability (Crossland et al., 2009, Crossland et al., 2004, Crossland and Rubin, 
2002).  The advantage of the BCEA calculation over the Fujii’s classification is 
that it is based on a mathematical model used in statistics to describe movement 
of variables; however, it is not related to any clinical classification in MP. 
 
The common formula used to calculate BCEA (Steinman, 1965) is: 
 
𝐵𝐶𝐸𝐴 = 2𝑘𝜋𝜎𝐻𝜎𝑉(1 − 𝜌
2)1/2 
 
where 𝐵𝐶𝐸𝐴 is the bivariate contour ellipse area, 𝜎𝐻 is the standard deviation of 
point location over the horizontal meridian, 𝜎𝑉 the standard deviation of point 
location over the vertical meridian, and 𝜌 the product-moment correlation of 
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these two position components. The value 𝑘 defines the limit for the ellipse and 
is dependent upon the probability area chosen given by: 
 
𝑃 = 1 − 𝑒−𝑘 
 
where 𝑒 is the base of the natural logarithm, from where, 
 
𝑘 =  −ln (1 − 𝑃) 
 
This method assumes that fixation points are normally distributed. Different 
authors have used different probability (P) values, such as 0.63 (Steinman, 1965, 
Kosnik et al., 1986), 0.68 (Crossland et al., 2009, Crossland et al., 2004, 
Crossland and Rubin, 2002), or 0.95 (Schuchard and Raasch, 1992). The clinical 
and statistical significance of such P values have never been reported for MAIA 
microperimetry. 
 
The MAIA reports two BCEA indices with proportional values of 63% and 95% 
converted into degree units. Reference databases of macular sensitivity values 
have been reported, allowing the correlation of location-specific data from the 
average threshold sensitivity in normal eyes to those data acquired from eyes 
with different stages of AMD, however there are no studies reporting similar 
normative reference for the BCEA fixation indices, for such reason, we 
conducted a study to establish a reference database for fixation stability 
measured with the BCEA metric in a group of normal subjects tested with the 
MAIA microperimeter (Morales et al., 2016). 







This was a multisite, cross-sectional, observational, prospective study which 
included normal healthy subjects without signs of ocular pathology, aged 19 to 
86 years from June 2012 to June 2016. The clinical study sites involved were 
located at Nottingham (U.K.), Crete (Greece), Slidell, Louisiana (U.S.A.), and 
Milan (Italy).  
 
A total of 358 participants with normal visual acuity or corrected to normal 
(20/20 or better), mean spherical equivalent refractive error of -3.06±1.36 
(range, -9.50, 5.28) and with no history of any visual abnormalities, were tested 
for fixation stability and macular light threshold sensitivity using the MAIA 
microperimeter device. The MAIA automatically corrects for refraction errors 
in the spherical equivalent of -15 to +10 diopters; therefore, such range was part 
of the inclusion criteria. Only one eye of each patient was tested for inclusion 
within the reference database. The eye with the better visual acuity was selected, 
and the right eye was chosen if visual acuity was identical in both eyes. Thirty-
one patients were excluded from the analysis due to their low reliability index in 
the MAIA testing, established by CenterVue as a fixation loss value indicated 
by the percentage of stimuli reported as seen when a stimulus is projected onto 
the optic nerve head (blind spot). Microperimetry, through the retinal landmark 
tracker, compensates for eye movements in the location of stimuli projection, 
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hence gaze deviation will not interfere while testing the blind spot. In essence, 
the fixation loss value is a validation measure of the test subject's compliance 
with reporting only those stimuli that are potentially visible. The test is 
considered reliable when such index is above 70% (MAIA Operator’s Manual). 
A total of 326 eyes were included in the analysis after the exclusions. 
Patient examination data was anonymised prior to inclusion within the database 
in order to protect patient privacy. Written informed consent was obtained from 
all participants, and local Bioethics Board approval was obtained as required for 
all sites involved in the study. The study was performed in accordance with the 
tenets of the Declaration of Helsinki. 
 
Equipment and procedures 
A fully automated MAIA examination was performed to assess LTS and FS 
using the MAIA standard macular grid pattern (37 stimuli points) over 10 retinal 
degrees (±5° around the macula). In the first 10 seconds of the examination, the 
MAIA microperimeter performs a fixation test in which a central point of 
reference of the average retinal position is calculated and labelled as PRL_initial 
(PRLi); subsequently the projection of the pre-selected stimuli grid map begins 
with the grid centred on such PRLi. On completion of the test, the centre of the 
mass (barycenter) of the total fixation points is calculated and defined as 
PRL_final (PRLf), which corresponds to the foveal area in normal 
subjects.(Morales et al., 2013) The projection strategy was the standard 4-2 and 
the examination was performed without dilation, in a darkened room (mesopic 
conditions). Patients were instructed to stare at the centre of the fixation target 
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during the examination. The fixation target consists of a 1° diameter red circle 
with light intensity of 10 ± 3 apostilb (asb).  
 
The MAIA can project stimuli targets with a maximum luminance of 1000 asb 
and with a stimulus dynamic range of 36 decibels (dB). The MAIA 
microperimeter utilizes a scanning laser ophthalmoscope (SLO) technology to 
image the retina to a field of 36°; it has an automatic compensation of refractive 
error between -15 and +10 diopters (D). The automated retinal eye-tracking 
system samples and corrects for eye movements at 25 Hz with respect to the 
positioning of stimulus targets. The fixation location is calculated from the eye-
tracking output, and plotted 25 times per second as a cloud of fixation points 
(CFP) describing the fixation pattern overlaid onto a reference SLO retinal image 
acquired at the start of the test. The average examination time is 5 minutes, 50 
seconds; therefore, the CFP may contain more than 8700 points (Fig. 4.1). 
 
Primary outcomes of the study were the four MAIA fixation indices: P1, P2 and 
the two BCEA proportional values of 63% and 95%. Secondary outcomes were 
the average of sensitivity, distance between the PRLi and PRLf (ΔPRL) (Morales 
et al., 2013), the MAIA examination time and the BCEA orientation, which 
corresponds to the angle between the ellipse major axis (EMA) and the 
horizontal axis (HA) of the visual meridian, where values between 0° and +90° 
correspond to an angle measured counter clockwise between the HA and the 
EMA; values between 0° and -90° are measured clockwise between the HA and 
the EMA; 0° corresponds to a horizontal orientation, and 90° to a vertical one. 
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Figure 4.1  MAIA image with CFP 
Image of the MAIA microperimeter showing the cloud of fixation points (CFP) 
and both BCEAs (63% and 95%), which lie at approximately the same foveal 




All data were exported from the MAIA system as raw data (MAIA software 
version 1.7.0) and collected into a Microsoft Excel spreadsheet (Microsoft, 
Bellevue, WA). The statistical analysis was performed with linear regression and 
Pearson’s product-moment correlation coefficient. A p-value less than 0.05 was 
considered statistically significant. Linear regression, best-fit values, 95% 
confidence and prediction intervals, correlation coefficient of determination, and 
analysis of variance (ANOVA) with 95% CI were calculated and plotted using 








When data from all included eyes (n = 326) were analysed (Table 4.1), we found 
average areas of 0.80 deg2 (min = 0.03, max = 3.90, SD = 0.68) for the parameter 
BCEA@63%, and 2.40 deg2 (min = 0.20, max = 11.70, SD = 2.04) for 
BCEA@95% (Figure 4.2). The average values of P1 and P2 were 95% (min = 
76, max = 100, SD = 5.31) and 99% (min = 91, max = 100, SD = 1.42), 
respectively. The maximum fixation value (100%) was recorded in 65 (20%) 
cases of P1 and 199 (61%) cases of P2. MAIA P1 & P2 linear regression analysis 
showed a more sensitive P1 index than P2 (Figure 4.3). The average of LTS was 
29 dB (min = 18, max = 34, SD = 2.60). The mean ΔPRL was 0.2° (min = 0.0, 
max = 1.0 SD = 0.16) (Fig. 4.4). The angular orientation of the BCEA was 
variable with a mean angle of 3° (min = -90, max = 90, SD = 53.83). The mean 
examination time for each eye was 5 minutes, 50 seconds (min = 4 minutes, 
2seconds, max = 10 minutes, 40seconds, SD = 59 seconds). 
 
Linear regression and summary statistics for all parameters of fixation stability (BCEAs, P1 and 
P2), light threshold sensitivity (LTS), distance between the initial and final PRL ( ‡ ), angle of 
inclination for the BCEA ( § ), and examination time. (* = Coefficient of determination. † = 
Shapiro–Wilk test for normality). 
 
Table 4.1  Linear regression and summary statistics 
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The ANOVA comparisons of the FS means within the age groups were highly 
significant for the indices P1, BCEA@63% and BCEA@95%, but less 
significant for P2 (Table 4.2). 
 
 
Mean and standard deviation of all fixation stability parameters for different age groups. 
 
The Pearson's product moment test showed an almost perfect correlation index 
(r = 0.999) between BCEA@63% and BCEA@95%. The P1 index showed a 
very strong correlation with BCEA@63% (r = -0.924), as well as with 
BCEA@95% (r = -0.925). P2 demonstrated a slightly lower correlation with 
both BCEA@63% and BCEA@95% with r values of -0.874 and -0.875 
respectively. The correlation between P1 & P2 (r = 0.792) was lower than that 
found with the BCEA indices. Finally, low correlations (r < 0.28) between any 
of the fixation indices and the patient’s age were found. 
 
Table 4.2  Fixation stability in age groups. 
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Figure 4.2  BCEA in normals 
The BCEA proportional values of 63% shows a mean of 0.80 ± 0.68 deg2, whilst the BCEA 
proportional values of 95% shows a mean of 2.40 ± 2.04 deg2. Note the distribution similarity 




Figure 4.3  P1 in normals 
P1 shows mean values of 95% ± 5.31, whilst P2 shows mean values of 99% ± 1.42. Note that the 
R-squared value of P1 (0.07), fits better the regression model than P2 (0.04), which demonstrates 





Currently available MP instruments can deliver four or more different indices of 
fixation stability, making the comparison to a reference database overly 
complicated and somewhat arbitrary in terms of a standard. As such, the MAIA 
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MP delivers two PFP indices (P1 and P2) as proposed by Fujii (Fujii et al., 2002), 
as well as two BCEA indices (63% and 95%) as proposed by Crossland 
(Crossland and Rubin, 2002). The PFP indices allow the classification of fixation 
as stable or not stable, but the BCEA indices are not related to any clinical 
stability standard at the present. This study reports a normative reference 
database for BCEA fixation stability indices for the MAIA instrument. 
 
In addition, we explored the strongest correlations among all fixation indices, 
highlighting the near-perfect correlation between BCEA@95% and 
BCEA@63%, as well as the very strong Pearson’s power product between 
BCEA@95% and P1. Moreover, the P1 and P2 linear regression analysis showed 
a more sensitive P1 index than P2, with P2 having a higher ceiling effect than 
P1 (100% maximum percentage). 
 
Various geometric and statistical models using multi-variable datasets have been 
used to simplify and describe the complexity and dynamic nature of movement 
sampling. The Bivariate Contour Ellipse Area (BCEA) model describes the 
horizontal and vertical displacements of the retinal position over the course of 
time during fixation attempts. By describing fixation stability in this manner, the 
BCEA has a graphical advantage in its ability to represent a specific proportion 
of the total CFP dataset points collected. The dimensions and orientation of the 
BCEA illustrate the total extent of the retinal area used by subjects while 
attempting to maintain constant fixation.  
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Crossland et al. (Crossland and Rubin, 2002) suggested the analysis of fixation 
stability by means of BCEA instead of PFP after demonstrating a strong 
relationship between fixation stability measured with BCEA and many 
parameters of reading ability, as well as a very poor correlation between PFP 
indices with any of the standard parameters of reading ability in Low Vision 
patients. 
 
Tarita-Nistor et al. (Tarita-Nistor et al., 2008) have stated that the BCEA 
description of fixation is scientifically more acceptable than the Fuji 
classification due to the analysis being based on a well-known mathematical 
model versus the quantification of fixation points falling into an arbitrarily 
selected fixed circular area of 1° and 2° in radius. However, the main advantage 
of the Fuji metrics is that it has established a differentiation between normal and 
non-normal fixation with cut-off values of 75% within 1° radius from the 
centroid of the fixation dataset. 
 
According to the above, the discrepancy between our MAIA-based findings and 
the cut-off values of stable fixation proposed by Fujii (Fujii et al., 2002) is 
worthy of comment. Our studied population demonstrated higher P1 values 
(fixation points within 1° radius) than those proposed by Fuji (95±5% vs 75%) 
while the P2 index (fixation points within 2° radius) reached a celling effect in a 
high number (61%) of the studied subjects. In contrast, our BCEA values showed 
only 1 participant who reached the floor effect in the BCEA@63% while none 
of the subjects reached the lowest limiting value in the BCEA@95%. 
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A literature search reveals reports of different BCEA ellipse values for normal 
control groups evaluated with microperimetry systems other than the MAIA 
(Tarita-Nistor et al., 2008, Dunbar et al., 2010, Cutini et al., 2014). It is 
noteworthy that some of these previously reported results are based on a fixation-
only test lasting between 10 and 30 seconds, and the amount of data collected is 
less than 800 points. In contrast, the MAIA-based BCEA ellipse is derived from 
a CFP with more than 8,000 data points, a greater than 10-fold difference in data 
sampling. Furthermore, because the complete MAIA microperimetry 
examination has a median duration of 5.5 minutes, fixation fatigue plays a major 
role in creating a larger BCEA ellipse.  
 
In particular, the majority of the participants in our study were naïve clinical 
patients with no previous experience in maintaining fixation for long periods of 
time. Other possible explanations for BCEA outcome discrepancy include 
differences in the N values of the study groups, the motivation and inclusion 
criteria for selecting study participants, differences in the fixation target 
dimensions and appearance, and other protocol differences that are beyond the 
scope of this report.  
 
Tarita-Nistor et al. (Tarita-Nistor et al., 2008) reported in a study with the Nidek 
MP1 (Nidek, Gamagori, Japan), 10 experienced healthy controls (age 41 ± 18.1 
years) with very small mean BCEA_68% values (0.053 ± 0.022 deg2).This is 
different from the results obtained by Dunbar et al., (Dunbar et al., 2010) who 
reported the BCEA@68% values of 16 normally sighted volunteers with the 
Rodenstock SLO and the Nidek MP-1, showing different values among both of 
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their studied instruments which are even larger than our findings (3.3 deg2 with 
the Rodenstock and 5.0 deg2 with Nidek). 
 
Liu et al. (Liu et al., 2015) reported BCEA data in subjects with and without 
maculopathies with two different systems, the MP-1 and optical coherence 
tomography (OCT)/SLO. The technologies behind the two instruments are 
different. The MP-1 uses an infrared camera to image the retina controlled by a 
25-Hz eye tracker, which is the same eye-tracker frequency found in the MAIA. 
The second is an SLO imaging device with a much slower eye tracker (8 Hz). 
Such a study was based on a fixation-only test of 20 seconds, which is largely 
different from the examination time (mean 350 seconds) studied in this article. 
Their results suggest that the patient’s pattern of FS may be the same, although 
calculated with different technologies. Furthermore, the authors normalized their 
data with a log transformation of the BCEA units (minutes of arc2) to undertake 
statistical comparison of the two technologies. In our study, the whole dataset 
was analysed using the MAIA output layout with the purpose of establishing 
reference values for the MAIA that is useful to clinicians. 
 
Similar to the findings reported by Cutini et al (Cutini et al., 2014), who 
evaluated BCEA indices in the MP-1 microperimeter (Nidek), our study 
demonstrates a weak, but statistically significant correlation between the fixation 
indices and the patient’s age. 
 
Our study data, which was collected from multiple clinical sites, represents true 
characteristics of the clinical data that will be encountered by eye care 
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professionals using the MAIA system. Because of the aforementioned protocol 
and technical differences among various systems, the quality and accuracy of 
fixation results reported for other microperimetry devices are questionable and 
therefore not directly relatable to the MAIA system. 
 
In light of these correlations, we conclude that in clinical practice, the single 
parameter of the BCEA@95% should be considered as accurately reporting 
fixation stability and serves as an age-dependent reference database of normal 
subjects with a cut off area of 2.4 ± 2.0 deg2 in MAIA microperimetry. The study 
established an important age-related normative standard for future fixation 
stability studies of diseased and disease-suspect eyes analysed with BCEA in the 
MAIA microperimetry (Figure 4.4). 
 
 
Mean BCEA@63% and BCEA@95% values ± 95% confidence interval (CI) of the mean 
in the different age groups. 
 
  
Figure 4.4  BCEA vs age 









The retinal area used during any fixation attempt, in cases of central vision loss, 
defines the preferred retinal locus (PRL). It is presumed that during prolonged 
fixation attempts there may be various representative reference points within the 
PRL area. The MAIA microperimeter defines two main PRL reference points 
during any light threshold sensitivity (LTS) examination. However, the 
understanding of its clinical validity is incomplete (Morales et al., 2013). 
 
Several different retinal diseases affecting the macula will interfere with the 
fixation of the eye. These include retinal dystrophies, in particular: Stargardts’ 
disease, age-related macular degeneration AMD, retinal vascular occlusions 
(RVO), diabetic macular oedema (DME), and intraocular inflammations. 
Patients with visual loss from the foveal involvement of these diseases tend to 
adopt eccentric viewing by developing an eccentric PRL. Previous studies have 
identified eccentric PRLs. However, the characteristics of these PRLs are still 
not fully understood, or clearly defined. Current knowledge suggests that PRLs 
may change depending on the type of macular disease, levels of illumination, 
and the tasks being performed (Sunness et al., 1996, Lei and Schuchard, 1997, 
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Safran et al., 1999, Schuchard et al., 1999, Deruaz et al., 2002, Midena et al., 
2004, Crossland et al., 2011a).  
 
During MP examinations, patients are asked to fixate on a target displayed inside 
the instrument. While patients attempt fixation, eye-tracking algorithms 
compensate retinal movement. Image sampling is carried out in real time. The 
center of all retinal positions is plotted as a cloud of fixation points (CFP) 
describing the fixation pattern overlaid onto a reference retinal image acquired 
at the start of the test. The graphical result of the CFP is nominated in MP 
instruments as the PRL. Hence, the resulting PRL describes patient’s fixation 
characteristics in terms of location (central or eccentric) and stability (stable, 
relatively stable or unstable) (Fujii et al., 2002). In addition, the PRL graphic 
representation provides information on size of PRL span density, as well as PRL 
span orientation. 
 
The MAIA is the only MP system that offers automatic estimates on PRL 
characteristics during early and late fixation. It utilizes a Scanning Laser 
Ophthalmoscope (SLO) to image the retina while projecting Goldman III size 
stimuli directly on the retina by means of a white LED. The eye tracker speed is 
25Hz, which is the maximum effective tracking speed to synchronise the SLO 
imaging system. In the first 10 seconds of the examination, the MAIA performs 
an initial fixation test in which a central point of reference of the average retinal 
position is calculated and labeled as PRL_initial (PRLi); subsequently the 
projection of the pre-selected stimuli grid map begins using the PRLi as the 
center of the stimuli grid array. On completion of the test, the center of the mass 
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(barycenter) of the total plotted CFP is calculated and nominated as PRL_final 
(PRLf) which is at the same time the reference point of fixation stability 
calculations, including the parameters used to classify fixation in stable, 
relatively unstable and unstable as described in previous chapters (Fujii et al., 
2002). 
 
The aim of this study was to improve understanding of the clinical validity of 
the MAIA PRLs. The location of both PRLs (initial and final), and their 
correlation with fixation stability and visual acuity in a group of patients with 






Sixty-five eyes from forty-one (41) patients attending the Retina and Low Vision 
Clinics of the Queens Medical Centre, Nottingham, were investigated in this 
study. They included 26 (40%) male and 39 (60%) female patients (mean age 
70, SD = 13.82), with varying retinal pathologies affecting the central vision 
such as dry AMD, neovascular AMD (nvAMD), non-AMD choroidal 
neovascularization, anterior uveitis with macular oedema, chorioretinitis, 
diabetic macular oedema, and branch retinal vein occlusion (BRVO) with 
macular oedema. All the participants signed an informed consent form and were 
assessed for visual function with the MAIA microperimetry. The inclusion 
criteria for the study were: adults over 21 years old with macular diseases as 
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listed above, and with a visual acuity (VA) from 0.0 to 1.6 LogMAR. There was 
no limitation in terms of race, sex or ethnicity. Excluded from the study were 
subjects with moderate to severe cataract (over grade 2 LOCS) or with other 
causes of opaque optical media and patients who were uncooperative or unable 
to use the MAIA after instruction. 
 
Equipment and Procedures 
All patients underwent the MAIA microperimetry standard exam grid consisting 
of the projection of 37 Goldman III size stimuli points with a presentation time 
of 200 ms covering the central 10° degrees of vision. The test contains one 
central stimulus and three concentric rings with 12 evenly distributed stimuli 
separated at 1°, 3° and 5° from the centre. During test, patients are asked to gaze 
steadily at the centre of the 1° red circle fixation target, which is concentric to 
the instrument’s optical path. The MAIA examination starts with 10 seconds of 
fixation test with no stimuli projection in order to define the initial PRL (PRLi). 
Once the PRLi is estimated, the projected stimuli grid map is automatically 
centred in such PRLi and the randomized stimuli projection starts. At the end of 
the examination, the final PRL (PRLf) is calculated as the barycenter of all the 
plotted fixation points (Figure 5.1). MP outcomes are presented as the LTS of 
individual stimulus, their average value, the CFP, the reference point of both 
PRLs (initial and final) and the estimates of fixation stability (stable, relatively-
unstable, or unstable). 
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Microperimetry examination outcomes: A) Normal patient showing PRL_initial (PRLi) and 
PRL_final (PRLf) in the same anatomical position with a mean light threshold sensitivity (LTS) 
= 29.8 dB and stable fixation with fixation points in P1 and P2 more than 95%. B) Patient with 
GA and eccentric preferred retinal locus (PRL); PRLi and PRLf in different loci, mean LTS = 
2.9 dB and unstable fixation with P1 = 23%, P2 = 70% of fixation points. In both cases, the 




Patient characteristics are summarized with percentages, means, and standard 
deviations. Association of the FS and VA are evaluated using linear regression. 
All statistical analyses were performed using SPSS16 (IBM), and the 





A total of 41 patients (n = 65 eyes) completed the microperimetry test within an 
average time of 6 minutes. PRLi and PRLf values were calculated by the MAIA 
Figure 5.1  PRL initial and final 
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instrument after the first 10 seconds, and at the end of the test respectively. Forty-
two eyes (65%) of the studied population had diagnosis of dry AMD or nvAMD; 
75% of these subjects showed a different locus of PRLi and PRLf. 
 
Forty-four eyes (68%) with mean age = 66yrs (SD = 14), different visual acuities 
(mean = 0.24, min = 0.0, max = 1.60 LogMAR) and different average LTS (mean 
= 22.5, min = 9.4, max = 29.9 dB), demonstrated almost identical locations for 
PRLi and PRLf, and were classified as having stable fixation (mean P1 = 95.1, 
P2 = 99.2) (Figure 5.2). 
 
Eyes (44) with both PRL_initial (PRLi) and PRL_final (PRLf) located over the central macula 
demonstrated good fixation stability (P1 and P2 < 75%) despite the wide range of threshold 
sensitivity values (min 9.4 dB, max 29.8 dB).  
 
Forty eyes (62%) were found to locate both PRLs in the same anatomical 
position corresponding to the fovea centralis (VA mean = 0.19 LogMAR, SD = 
0.26, LTS mean = 23.46 dB, SD = 5.28) (Figure 5.3A). Another four eyes (6%) 
with stable fixation had central geographic atrophy (cGA) with both PRLs 
located in the same extrafoveal loci (VA mean = 0.79 LogMAR, SD = 0.55, LTS 
Figure 5.2 Fixation vs sensitivity 
75 | P a g e  
 
mean = 13dB, SD = 3.36) (Figure. 5.3B). Two eyes with stable fixation, both 
with VA = 0.1 LogMAR (LTS 19.5 and 25.3 dB respectively), had the PRLi 
located over the foveal area, whilst the PRLf was in a different locus.  
 
 
Two patients classified as having stable fixation with different PRL characteristics. A) Patient 
with GA with both PRL_initial (PRLi) and PRL_final (PRLf) in the same eccentric (inferior) loci 
with very stable fixation (P1 = 99%, P2 = 100%), low mean light threshold sensitivity (LTS) and 
visual acuity (VA) due to the geographic atrophy, LTS = 15.4 dB, VA = 0.7 logMAR. B) Patient 
with nvAMD having PRLi located over the foveal area, whereas the PRLf is located inferiorly 
about 1° with P1 = 86%, P2 = 99%, LTS = 19.5 dB, and VA = 0.1 logMAR. 
 
From the total studied population (n = 65), 20 (31%) eyes demonstrated different 
locations of PRLi and PRLf (Fig. 5.4), including 11 eyes (55%) with nvAMD, 4 
(20%) with dry AMD, 3 (15%) with disciform degeneration (end stage nvAMD) 
and 2 (10%) with DME. The mean distance from PRLi to PRLf was 2.27° (SD 
= 1.43), with a mean VA = 0.75 LogMAR (min = 0.1, max = 1.9) and a mean 
LTS = 12.06 dB (SD = 6.46). Eighteen of these 20 eyes (90%) were classified 
as having unstable or relatively-unstable fixation and only 2 eyes (10%) had a 
Figure 5.3 PRLi-PRLf near and far 
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stable fixation, both with VA = 0.1 LogMAR (mean LTS 19.5 and 25.3 dB 
respectively) (Figure 5.4). 
 
Patients with different location of PRL_initial (PRLi) and PRL_final (PRLf). A) Patient 
diagnosed with nvAMD and ERM with separation distance of 2° between the preferred retinal 
loci (PRLs), visual acuity (VA) = 0.3 logMAR, mean LTS = 21.9 dB, and a relatively unstable 
fixation (P1 = 40%, P2 = 84%). B) Patient diagnosed with dry cGA AMD; PRLi located adjacent 
to the geographic atrophy and PRLf separated 3° from PRLi, VA = 0.66 logMAR, mean LTS = 
7.4 dB, and an unstable fixation (P1 = 22%, P2 = 51%). 
 
 
Fourteen (21.5%) eyes of the studied population had cGA (mean VA = 0.89 
LogMAR, SD = 0.36). All 14 (100%) presented the PRLi immediately adjacent 
to the dense scotoma. 10 (71%) of these cases showed different PRLi and PRLf 
loci (PRLi to PRLf distance min = 0.5°, max = 5°) with an unstable or relatively 
unstable fixation. The other 4 (29%) shared the same eccentric PRLi & PRLf 
loci with a stable fixation. 5 (36%) cases showed the PRLf in a more eccentric 
locus away from the cGA limit (Fig. 5.4B). Those patients with cGA, 
demonstrated a visual acuity reduction as the distance between the PRLi from 
the fovea centralis increases. 
Figure 5.4  PRL eccentric 
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Six cases with non-central GA (4 of whom had been diagnosed with nVAMD 
secondary to angioid streaks), demonstrated a stable fixation (P1 > 86%, P2 > 
96%) with both PRLs over the foveal centralis. 
 
Patients classified as having an unstable and relatively-unstable fixation 
demonstrated that as the distance among PRLi and PRLf increases, VA (Figure 
5.5A), LTS (Fig. 5.5B), and FS (Fig. 5.5C) tend to decrease. However, the mean 
LTS and VA may have a wide range of values when both PRLs are located in 
the same position showing a stable fixation. 
 
 
Graphics show that when the distance between PRL_initial (PRLi) and PRL_final (PRLf) is 
minimal, visual acuity (A) and threshold sensitivity (B) may have a wide range of values, whereas 
they tend to decrease, as well as fixation stability (C), when the distance between both preferred 
retinal loci (PRLs) increases. 
 
Figure 5.5 Distance PRLi & PRLf 
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VA showed a tendency to decrease when the distance between the PRLi and the 
fovea centralis increases Figure 5.6A), as well as when FS (Fig. 5.6B) and LTS 
(Fig. 5.6C) decrease. Normally, the greater the distance between PRLi and PRLf, 
the lower the fixation stability. However, there may be cases where the fixation 
stability is low, even when the distance between both PRLs is not large, 
particularly in cases where the PRL is located away from the fovea centralis 
(Figure 5.7). 
 
Visual acuity shows a tendency to decrease when the distance between the PRL_initial (PRLi) 
and the fovea centralis is increased (A), and also when fixation stability (B) and threshold 
sensitivity (LTS) (C) decrease. 
 
 
Figure 5.6  VA linear regresion 
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Graph shows that when there is no distance between the PRL_initial (PRLi) and PRL_final 
(PRLf), the fixation is stable (P1 = 75%), and normally, the greater the distance between PRLi 
and PRLf, the lower the fixation stability, although our study showed 1 case with small preferred 





Previous studies have characterized PRLs in eyes with subnormal vision. Of 
special interest are the temporal characteristics of PRLs during same or 
consecutive fixation attempts. Different authors have stated the importance of 
the analysis of FS and fixation location in patients with eccentric PRL as 
essential predictors during the evaluation of the effects of treatment (Tarita-
Nistor et al., 2009a, Greenstein et al., 2008). The analysis of PRLi and PRLf 
combines both FS and location, and may be useful information to complement 
prognosis data for visual outcomes in the treatment of pathologies affecting the 
central vision. In the assessment of retinal function, the anatomical location of 
PRLi and PRLf may be important because these fixation characteristics may 
Figure 5.7  Fixation stability vs PRL distance 
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reflect the possible association with oculomotor functions that ultimately dictate 
the span and direction of the PRL and FS. 
 
The MAIA instrument by design allows identification of locations for the PRL 
at different stages of fixation (PRLi = 10 seconds, PRLf > 5 minutes) under same 
testing circumstances. To the best of our knowledge, this is the first study to 
characterize changes in PRLs during the course of a prolonged fixation attempt 
using microperimetry. 
 
Eyes with both PRLi and PRLf close to each other are noted to have stable 
fixation located mostly over the fovea centralis. However, patients with eccentric 
PRL may also have both the PRLi and PRLf in the same anatomical location 
showing eccentric but stable fixation. Eyes with PRLi and PRLf far from each 
other are noted to have, as a rule, unstable fixation mostly located on the 
peripheral retina. Interestingly, LTS may not be related to fixation characteristics 
particularly in cases of stable fixation. These characteristics may be important in 
eccentric fixation training. 
 
The location of PRL being immediately adjacent to the geographic atrophy (GA) 
had been previously reported (Timberlake et al., 1987). This is supported by our 
finding that at least 1 of the PRLs in all cases of cGA (except 1) was located 
immediately adjacent to the GA. However, a large number (71%) of the eyes 
with cGA presented unstable or relatively unstable fixation with different PRLi 
and PRLf loci, although some (29%) shared the same eccentric PRLi and PRLf 
loci showing stable fixation. 
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Previously, PRLs had been reported as “multiple” because they changed 
characteristics according to the type of macular disease, levels of illumination, 
and activity in which the patient is engaged (Sunness et al., 1996, Lei and 
Schuchard, 1997, Safran et al., 1999, Schuchard et al., 1999, Deruaz et al., 2002, 
Crossland et al., 2011a, Markowitz et al., 2011). Lei and Schuchard found cases 
with 2 different PRLs depending on the brightness of objects used in visual tasks 
(Lei and Schuchard, 1997). Similarly, Safran et al., and Deruaz et al., found 
multiple PRLs during the reading process; in both studies, 2 well-defined PRLs 
were located in different retinal zones (Safran et al., 1999, Deruaz et al., 2002). 
Conversely, our study has demonstrated cases with 2 different loci of high 
density of fixation points, within the same PRL span, in 2 different times of the 
same examination. 
 
Previous studies have demonstrated that VA can vary depending on the FS and 
location (Tarita-Nistor et al., 2009a). Our results show how VA tends to decrease 
as the distance between both PRLi and PRLf increase. However, further studies 
are needed to fully correlate the behaviour of both of the PRLs and VA during 
different stages of the pathology, treatment, and rehabilitation process. 
 
It is important to note that the studies of the PRL during the fixation attempt with 
microperimetry have been monocular; thus, the fixation characteristics in 
stereoscopic conditions remain to be explored in the future. The PRL is the 
graphic representation of all the retinal area used during a fixation attempt by 
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patients with compromised central vision. Characteristics of fixation, stability, 
and location appear to be dependent on the pathology and affect visual acuity.  
 
The importance of defining more than 1 reference point within the whole PRL 
area (PRLi and PRLf) is to give eye care practitioners a better understanding of 
the dynamic of the visual function. The representative points, PRLi and PRLf, 
may vary at different stages of fixation during prolonged fixation attempts. The 
PRLs are important and need to be considered during retinal functional 
assessment. 
 
This study suggests that when both PRLi and PRLf are located in the same 
position, fixation is stable. Conversely, a greater distance between the PRLi and 
PRLf may be a defining parameter of unstable fixation. The superimposition of 
clinical features and microperimetric characteristics such as LTS, FS, and 
fixation location may facilitate the determination of the differential impact of 
macular disorders and their corresponding VA. This could be relevant as 








6.Role of microperimetry in monitoring 






Age-related macular degeneration has, for many years, been the leading cause 
of blindness and visual disability in the western world (Bourne et al., 2014, Klein 
et al., 1999). Late AMD may be exudative, or neovascular form (nvAMD), 
which is typified by development of choroidal neo-vascularization (CNV), or 
geographic atrophy (GA), the advanced stage of dry AMD. The number of 
people with late AMD in Europe will increase from 2.7 million in 2013 to 3.9 
million by 2040 (Colijn et al., 2017), whilst patients with sight loss secondary to 
nvAMD are expected to increase from 145 697 to 189 890 by the end of the 
decade in the UK (Minassian et al., 2011). Similarly, diabetic retinopathy (DR) 
is the commonest cause of visual impairment in persons below the age of 65 
years; retinal vein occlusions (RVO) comes second. Treatment outcomes have 
improved considerably with the introduction of intravitreal therapies that inhibit 
vascular endothelial growth factor (VEGF) [thought to be the central mediator 
of vascular permeability and neovascularisation in these retinal vascular 
diseases], and inhibitors of inflammation e.g. intravitreal dexamethasone 
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implant (Ozurdex, Allergan). Other macular pathologies, including choroidal 
neovascularization secondary to pathologic myopia and other CNV with 
pathophysiology similar to nvAMD receive anti-VEGF therapy similar that in 
nvAMD. Epiretinal membranes are treated with intravitreal injections (IVT) of 
Ocriplasmin, whilst diabetic macular oedema (DMO) and macular oedema (MO) 
secondary to RVO may be treated with either IVT anti-VEGF or intravitreal 
dexamethasone implant. Non-infectious intraocular inflammation (uveitis) with 
macular oedema or vitritis is treated with dexamethasone implant. 
 
In contemporary clinical practice, assessment of macular pathologies typically 
includes visual acuity (VA), fundal examination (biomicroscopy), and optical 
coherence tomography (OCT) at monthly follow up intervals (The Royal 
College of Ophthalmologists, 2009), following confirmation of diagnosis and 
initial treatment. It is generally accepted, however, that changes in either VA or 
OCT alone may not be the optimum parameter(s) for measuring visual function 
in AMD and other macular diseases as these parameters (VA and OCT 
measurements including central retinal thickness [CRT]) are dependent on 
function in limited parts of the macula.  
 
As described in earlier chapters MP assesses the sensitivity of the central retina 
and allows precise topographic correlations of macular anatomy and light 
sensitivity. In addition, retinal sensitivity, as measured by MP, may be more 
sensitive to changes in macular function than the conventional distance visual 
acuity because it assesses function in a larger retinal area. As such, retinal 
sensitivity could be a better indicator of practical visual capabilities for patients 
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with macular dysfunction as in AMD, retinal vein occlusions, diabetic 
maculopathy etc. Retinal images in MP are correlated with retinal functional 
characteristics such as retinal sensitivity, PRL and fixation stability (FS), even 
in cases when central vision (VA) is reduced as a consequence of macular 
pathologies (Schneider et al., 1996, Midena et al., 2004). 
 
A few investigators have reported the usefulness of MP in the management and 
follow-up of pathologies affecting the macula, including complementary 
changes in retinal sensitivity during intravitreal therapies (Winterhalter et al., 
2012, Karacorlu et al., 2010, Hatef et al., 2011, Landa et al., 2011, Ozdemir et 
al., 2012). However, until now, retinal morphology assessment with OCT is used 
as the main criterion, in addition to VA, in determining treatment outcomes by 
ophthalmologist during the initiation and continuation of therapy, or temporary 
cessation, and treatment termination. This practice has continued in spite of  a 
pilot study reported by Alexander et al., who reported a relationship between 
macular sensitivity measured with the MAIA  MP, central retinal thickness and 
VA in the maintenance phase of ranibizumab therapy, and hypothesized that 
deteriorating retinal sensitivity in patients with stable VA and central retina 
thickness, may be an indicator of subclinical disease activity (Alexander et al., 
2012). The MAIA identifies two PRLs (initial and final) in two different 
examination times. Our team has reported that eyes with both PRLi and PRLf 
close to each other are noted to have stable fixation located over the fovea 
centralis, whilst eyes with PRLi and PRLf far from each other (higher than 0.8°) 
are noted to have unstable fixation located eccentrically from the fovea (Morales 
et al., 2013). 






This was an observational, cross-sectional, descriptive, study of retinal function 
changes monitored with an MP system in a group of patients from the Macular 
Clinic of the Queen’s Medical Centre, Nottingham (U.K.), with treatable 
macular diseases, undergoing IVT for different retinal pathologies affecting the 
central vision. Local ethical board approval and written informed consent was 
obtained, and the study met the tenets of the Declaration of Helsinki.  
 
Participants 
One hundred and three patients, mean age 70.7 years (min = 37, max = 97) 
attending the Macular Clinic for intravitreal therapy of one or both eyes for 
specific pathologies (including nAMD, DMO, MO secondary to RVO, and 
VMT) were recruited. Inclusion criteria were as follows: no limitation to race, 
sex or ethnicity, adult age above 21 and below 99 years, OCT presence of 
macular oedema, patients willing to attend for follow-up MP examinations, 
patients undergoing treatment with IVT of anti-VEGF therapies, dexamethasone 
implants, and ocriplasmin. 
 
The exclusion criteria were: moderate to severe cataract (over grade 2) or other 
cause of opaque optical media, previous treatments in the particular eye with 
IVT of anti-VEGFs or steroids within the previous 6 months, or macular laser 
photocoagulation, and uncooperative patient. 
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Equipment and Procedures 
Before commencing the IVT injection therapy, all patients had a routine clinical 
evaluation including best corrected visual acuity (VA) (LogMAR at 4 metres), 
slit lamp biomicroscopy of the anterior and posterior segments, MAIA 
microperimetry and OCT examinations. Only one eye for each patient was 
evaluated. If both eyes were treated, only the right eye was selected for inclusion. 
Appropriate IVT was administered as clinically necessary, as recommended by 
the Royal College of Ophthalmologists guidelines.  
 
The selected MP test was the standard MAIA grid, which covers a diameter of 
10° on the retina, with 37 stimuli points distributed in 3 concentric rings of 12 
stimuli located at 1°, 3° and 5° from the centre (equivalent to 2°, 6° and 10° in 
diameter respectively) plus a central stimulus. The grid was automatically 
centred by the MAIA on the patient’s PRL_initial. (Morales et al., 2013). 
Distance between PRL_initial and PRL_final (PRLi-f ) on each MP test was 
annotated and used to determine if patents had foveal PRL (PRLi-f ≤ 0.8°), or 
eccentric PRL (PRLi-f > 0.8°) (Morales et al., 2013). 
 
MP assessments consist in asking the patient to look steady at a fixation target 
inside of the instrument, while white stimuli of Goldmann III size (0.46°) are 
projected at different light intensities, from 4asb to 1000asb, over the selected 
grid pattern. Patients are asked to press a response button whenever they perceive 
light stimuli. The result of the minimum perceived light stimuli in every point is 
defined as the retinal threshold sensitivity map measured in a decibel (dB) scale 
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with a 32dB dynamic range. If no light is perceived, the retinal sensitivity in that 
point is defined as scotoma (<0 dB). Threshold of normal vision is known to be 
29.78 ± 1.71dB when assessed with the MAIA (Smolek et al., 2010). 
Examinations were performed with the full threshold 4-2 projection strategy. 
During the whole process the eye movement is registered by the MAIA eye 
tracker defining FS and the PRL area. Two of the MAIA FS indices were 
annotated, the P1 and the BCEA@63% (Morales et al., 2016). Classification of 
FS is defined in the MAIA as stable, relatively stable, or unstable ((Fujii et al., 
2002). The follow-up test is an automatic reproduction of the stimuli grid over 
the same anatomical points projected during base line examinations. 
 
Assessments were schedule on base-line, and repeated as follow-up after 3 
months, 6 months, and 12 months. The studied variables were, MP light 
threshold sensitivity (LTS), FS indices of P1 and BCEA@63%, FS 
classification, distance between PRL initial and PRL final to evaluate foveal or 
eccentric fixation, central retinal thickness (CRT) on OCT (the average retinal 
thickness in the central 1mm of the ETDRS circle), and VA. 
 
Primary outcomes were variable comparisons between MP-LTS, CRT and VA 
from base line and month 3 after therapy. Secondary outcomes were 
comparisons of the same variables between months 3, 6 and 12 after therapy. 
Final outcomes were correlations between base line values of FS, CRT, with VA 
in months 3 and 12. Foveal or eccentric PRL and fixation stability was analysed. 
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Statistical Analysis 
Statistical analysis (GraphPadPrism_8.20) included standard errors, 95% 
confidence level of intervals with significance differences set as P < 0.05. 
Ordinary one-way ANOVA test was applied to evaluate significant difference 
among means of each evaluated variable. Paired, parametric, one-tailed t-test 
was performed to compare the means. Finally, correlations were analysed 
through Spearman’s rank-order coefficient (rs). The correlation strength was 
described for the absolute value of r as, very weak (0.00 to 0.19), weak (0.20 to 






Patients with poor MP reliability test, or who missed one or more study visits 
were excluded from the analysis. A total of 74 patients were analysed and 
divided in 4 groups according to the intravitreal therapy: 
Group 1 - IVT anti-VEGF drugs for nAMD. 
Group 2 - IVT dexamethasone implant for the treatment of DMO. 
Group 3 - IVT dexamethasone implant for the treatment of MO secondary to 
RVO. 
Group 4 - IVT ocriplasmin for the treatment of VMT and macular hole (MH). 
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Group 1 (Anti-VEGF for nAMD) 
Forty patients, mean age 72.8 ± 11.2 years, were included. The measured 
variables at baseline (BL) and 3 months (3M) after therapy were as follows:  LTS 
changed from 16.83 ± 5.96 to 16.82 ± 6.30 dB, CRT from 235 ± 70.3 to 237 ± 
91.5 μm, and VA from 0.36 ± 0.34 to 0.34 ± 0.32 LogMAR. The t-test showed 
no significant difference for any of the variables at 3M compared to BL, and 
include for LTS, t(39) = 0.01 p = 0.493; for CRT t(39) = 0.260 p = 0.398 and for 
VA t(39) = 0.84 p = 0.202 (Table 6.1).  
 
The one-way ANOVA test conducted to compare the effect of the studied 
variables at BL, 3, 6 and 12 months after treatment showed no significant effects 
between the same variable at different time points but with a significant 
interaction (correlation) within groups. For LTS, F(2.79, 109) = 0.124, p = 0.936, 
and F(39, 117) = 17.70, p < 0.0001. For CRT, F(2.06, 80.4) = 1.91, p = 0.153 
and F(39, 117) = 17.10, p < 0.0001. For VA, F(1.60, 62.5) = 2.27, p = 0.122 and 
F(39, 117) = 14.12, p < 0.0001).( Figure 6.1). 
 
Fig 6.1 Box & whisker ANOVA outputs from Group 1, where significance between groups is: no 
significant for LTS (p = 0.936), no significant for CRT (p = 0.153) and no significant for VA (p 
= 0.122). 
 
Figure 6.1  ANOVA results group 1 
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A Pearson’s product-moment correlation coefficient was computed to assess the 
relationship between the two fixation stability indices (P1 and BCEA), LTS, 
CRT and VA in base line (BL), with VA at 3 months (VA-3M), and 12 months 
(VA-12M) after initial treatment. P1-BL showed a strong correlation (r = -0.65) 
with VA-3M, and moderate correlation (r = -0.56) with VA-12M. Similarly, 
BCEA-BL showed moderate correlations with VA-3M (r = 0.50) and VA-12M 
(r = 0.53). LTS-BL showed moderate correlation with VA-BL (r = -0.42). Whilst 
CRT-BL showed very weak (r = -0.10) and weak (r = -0.20) negative 
correlations with VA-3M and VA-12M respectively. Overall, VA-BL had the 
strongest correlation with VA after treatment (r = 0.90).  A heatmap of the 
correlation matrix summarizes the results (Figure. 6.2).  
 
Correlation heatmap graphic in Group 1 showing Pearson’s coefficient between age, base line 
fixation indices (P1-BL and BCEA-BL), base line visual acuity (VA-BL), and visual acuity after 
3 (VA-3M) and 12 months (BL-12M). 
Figure 6.2  Correlations Group 1 
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Number of patients (%) in Group 1 with foveal PRL (blue) and non-foveal PRL (yellow) as 
demonstrated with microperimetry examinations during the studied time. 
 
 
Number of patients (%) in Group 1 with fixation stability classified as stable (green), relatively 
stable (yellow) and unstable (red) as demonstrated with microperimetry examinations during 
the studied time. 
 
Figure 6.3  Patients with foveal PRL in Group1 
Figure 6.4  Fixation classification in Group 1 
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Group 2 (Dexamethasone for DMO) 
Fifteen patients, mean age 72.0 ± 9.6 years, showed a difference in studied 
variables between BL and 3M after therapy as follows: LTS changed from 18.75 
± 3.84 to 19.56 ± 2.97 dB, CRT from 490 ± 188 to 327 ± 119 μm, and VA from 
0.54 ± 0.23 to 0.48 ± 0.25 LogMAR. The t-test showed, no significant difference 
for LTS, t(14) = 1.25 p = 0.116, but was significant for CRT with the effect t(14) 
= 3.72 p = 0.001, and not significant for VA t(14) = 1.24 p = 0.117 (Table 6.1). 
 
The one-way ANOVA test conducted to compare the effect of the studied 
variables on base line, 3, 6 and 12 months after treatment showed no significant 
effects between the same variable at different time points but with a significant 
interaction (correlation) within groups for LTS, F(2.10, 29.3) = 2.31, p = 0.115, 
and F(14, 42) = 13.40, p < 0.0001. However, it was significant for CRT and VA 
in both, between and within groups, with the effects F(1.64, 23.0) = 13.2, p = 
0.0003 and F(14, 42) = 8.22, p < 0.0001 for CRT, and for VA, F(1.59, 22.2) = 
4.16, p = 0.037 and F(14, 42) = 15.8, p < 0.0001 (Figure. 6.5). 
 
Box & whisker ANOVA outputs from Group 2, where significance between groups is: no 
significant for LTS (p = 0.115), significant for CRT (p = 0.0003) and significant for VA (p = 
0.037). 
Figure 6.5  ANOVA results group 2 




A Pearson product-moment correlation coefficient was computed to assess the 
relationship between the two fixation stability indices (P1 and BCEA), CRT and 
VA in base line (BL), with visual acuity three months (VA-3M), and 12 months 
(VA-12M) after treatment. P1-BL showed a strong correlation (r = -0.61) with 
VA-3M, and moderate correlation (r = -0.53) with VA-12M. Similarly, BCEA-
BL showed moderate correlations with VA-3M (r = 0.50) and VA-12M (r = 
0.45). CRT-BL instead showed moderate (r = 0.58) and strong (r = 0.70) 
correlations with VA-3M and VA-12M respectively. A heatmap of the 
correlation matrix summarizes the results (Figure. 6.6).  
 
 
Correlation heatmap graphic in the Group 2 showing Pearson’s coefficient between age, base 
line fixation indices (P1-BL and BCEA-BL), base line visual acuity (VA-BL), and visual acuity 
after 3 (VA-3M) and 12 months (BL-12M). 
 
Figure 6.6  Correlations Group 2 
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From the studied population (n = 15), microperimetry outcomes showed, 11 
(73%) patients with foveal PRL at BL examination, 9 (60%) at 3M after therapy, 
8 (53%) at 6M, and again 8 (53%) at 12M (Fig. 6.7). Fixation stability (FS) was 
classified as stable in 9 (60%) patients at BL, 9 (60%) at 3M, 6 (40%) at 6M, 




Number of patients (%) in Group 2 with foveal PRL (blue) and non-foveal PRL (yellow) as 
demonstrated with microperimetry examinations during the studied time. 
Figure 6.7  Patients with foveal PRL in Group 2 
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Number of patients (%) in Group 2 with fixation stability classified as stable (green), relatively 
stable (yellow) and unstable (red) as demonstrated with microperimetry examinations during 




Group 3 (Dexamethasone for MO related to RVO) 
Thirteen patients, mean age 58.8 ± 14.3 years, showed a difference in studied 
variables between BL and 3M after therapy as follows: LTS changed from 21.35 
± 4.88 to 23.05 ± 4.11 dB, CRT from 407 ± 147 to 317 ± 116 μm, and VA from 
0.62 ± 0.40 to 0.48 ± 0.36 LogMAR. The t-test showed, no significant difference 
for LTS, t(12) = 1.66 p = 0.061, but significant differences for both CRT and 
VA, t(12) = 2.00 p = 0.034, and t(12) = 1.88 p = 0.042. (Table 6.1). 
 
The one-way ANOVA test conducted to compare the effect of the studied 
variables at BL, 3M, 6M and 12M after treatment showed no significant effects 
Figure 6.8  Fixation classification in Group 2 
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between groups (therapy time) with a significant interaction within groups for 
LTS, F(2.21, 26.5) = 2.38, p = 0.107, and F(12, 36) = 8.71, p < 0.0001. CRT 
instead showed significance in both effects, F(2.11, 25.4) = 4.50, p = 0.019 and 
F(12, 36) = 2.84, p = 0.007. VA showed no significance between groups, 
however it was significant within groups, F(1.65, 19.9) = 3.55, p = 0.055 and 
F(12, 36) = 7.79, p < 0.0001 (Figure. 6.9). 
 
 
Box & whisker ANOVA outputs from Group 3, where significance between groups is: no 




A Pearson product-moment correlation coefficient was computed to assess the 
relationship between the two fixation stability indices (P1 and BCEA), CRT and 
VA in BL, with VA-3M, and VA-12M after treatment. P1-BL showed very weak 
correlation (r = -0.19) with VA-3M, and null correlation (r = 0.00) with VA-
12M. Similarly, BCEA-BL showed weak correlations with VA-3M (r = 0.27) 
and VA-12M (r = 0.04). Likewise, CRT-BL showed very weak (r = 0.02) and 
Figure 6.9  ANOVA results Group 3 
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null correlation (r = 0.00) correlations with VA-3M and VA-12M respectively. 




Correlation heatmap graphic in the Group 3 showing Pearson’s coefficient between age, base 
line fixation indices (P1-BL and BCEA-BL), base line visual acuity (VA-BL), and visual acuity 
after 3 (VA-3M) and 12 months (BL-12M). 
 
 
From the studied population (n = 13), MP outcomes showed, 8 (62%) patients 
with foveal PRL during BL examination, 11 (85%) 3M after therapy, 10 (77%) 
at 6M, and 10 (77 %) at 12M (Fig. 6.11). Fixation stability (FS) was classified 
as stable in 7 (54%) patients at BL, 10 (77%) at 3M, 10 (77%) at 6M, and 8 




Figure 6.10  Correlations Group 10 
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Number of patients (%) in Group 3 with foveal PRL (blue) and non-foveal PRL (yellow) as 




Number of patients (%) in Group 3 with fixation stability classified as stable (green), relatively 
stable (yellow) and unstable (red) as demonstrated with microperimetry examinations during 
the studied time. 
 
 
Figure 6.11  Patients with foveal PRL in Group 3 
Figure 6.12  Fixation classification in Group 3 
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Group 4 (Ocriplasmin for VMT and MH) 
Six patients, mean age 79.8 ± 10.8 years, showed a difference in studied 
variables between BL and 3M after therapy as follows: LTS changed from 17.77 
± 3.83 to 21.45 ± 2.26 dB, CRT from 295 ± 50.7 to 217 ± 27.9 μm, and VA from 
0.54 ± 0.14 to 0.32 ± 0.15 LogMAR. The t-test showed no significant difference 
with the following effects for LTS, t(5) = 1.62 p = 0.083; significant differences 
were observed at 3M for CRT t(5) = 3.23 p = 0.011 as well as  for VA t(5) = 
5.34 p = 0.001 (Table 6.1). 
 
The one-way ANOVA test conducted to compare the effect of the studied 
variables at BL, 3M, 6M and 12M after treatment showed for LTS no significant 
effects between the same variable at different time points but a significant 
interaction within groups (correlation) as follows, F(1.20, 6.0) = 2.63, p = 0.155, 
and F(5, 15) = 11.90, p < 0.0001. The opposite way was for CRT with a 
significant effect between the same variable at different time points groups but 
no effect within groups, F(1.37, 6.87) = 7.62, p = 0.023 and F(5, 15) = 2.47, p = 
0.079. Whereas VA showed significant difference in both effects, F(2.43, 12.2) 
= 19.6, p < 0.0001 and F(5, 15) = 8.93, p = 0.0004 (Figure. 6.13). 
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Box & whisker ANOVA outputs from Group 4, where significance between groups is: no 




A Pearson product-moment correlation coefficient was computed to assess the 
relationship between the two fixation stability indices (P1 and BCEA), CRT and 
VA at BL, with VA-3M, and VA-12M after treatment. P1-BL showed very weak 
correlation (r = -0.05) with VA-3M and VA-12M (r = 0.10). Similarly, there 
were no significant correlations for BCEA-BL with VA-3M (r = 0.09) and VA-
12M (r = 0.08), as well as the case for CRT-BL (r = -0.09) and (r = 0.08) with 
VA-3M and VA-12M respectively. Overall, VA outcomes did not show any 
correlation with any other measured variable, with the exception of base line 
VA.  A heatmap of the correlation matrix summarizes the results (Figure. 6.14). 
 
Figure 6.13  ANOVA results in Group 4 
102 | P a g e  
 
 
Correlation heatmap graphic in the Ocriplasmin group showing Pearson’s coefficient between 
age, base line fixation indices (P1-BL and BCEA-BL), base line visual acuity (VA-BL), and visual 
acuity after 3 (VA-3M) and 12 months (BL-12M). 
 
 
From the studied population (n = 6), MP outcomes showed, 2 (33%) patients 
with foveal PRL at BL examination, 15 (83%) at3M after therapy, 3 (50%) at 
6M, and 2 (33 %) at 12M (Fig. 6.15). Fixation stability (FS) was classified as 
stable in 1 (16%) patients at BL, 2 (33%) at 3M, 1 (16%) at 6M, and 1 (16%) at 








Figure 6.14  Correlations in Group 4 
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Number of patients (%) in Group 4 with foveal PRL (blue) and non-foveal PRL (yellow) as 
demonstrated with microperimetry examinations during the studied time. 
 
 
Number of patients (%) in Group 4 with fixation stability classified as stable (green), relatively 
stable (yellow) and unstable (red) as demonstrated with microperimetry examinations during 
the studied time. 
 
 
Figure 6.15  Patients with foveal PRL in Group 4 
Figure 6.16  Fixation classification in Group 4 





Descriptive statistics and one tailed t-test outcomes comparing the studied variables between 





There has been an incremental use of MP testing in clinical trials recently, as 
several authors have reported that test re-test capabilities of the same anatomical 
locus may be more efficient in MP than conventional standard automated 
perimetry. This is on account of the introduction of the retinal tracker system, an 
essential component of the MP design, which aids to compensate for eye 
movements during examinations.  
Table 6.1  Descriptive statistics 
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MP outcomes describe retinal function in terms of light threshold sensitivity and 
patient’s fixation capabilities. However, the majority of clinical studies which 
include MP testing, have predominantly reported outcomes of mean sensitivity 
in the selected grid, and correlations with VA and OCT macular morphology.  
 
The ETDRS Study Group defined 9 regions (sectors) of the macula for 
evaluation of changes in macular thickness in DR. The regions are located in 
three rings with diameters of 1, 3, and 6 mm. The 1 mm ring contains a 1 mm 
perifovea ring called the Central Retinal Subfield. In this study we have analysed 
the CRT which represents the average thickness within the central ETDRS 1 mm 
ring. Different methods have been described to calculate foveal size dimension, 
in essence studies using the contrast adjustment, or non-contrast adjustment 
(Fingler et al., 2009) have reported foveal diameter of 0.7mm and 1.02 mm 
respectively. Recently the size and shape of the foveal avascular zone (FAZ) 
determined by OCT angiography (OCTA) in normal subjects has reported the 
foveal size to be 0.749 ± 0.129 mm.. (Shiihara et al., 2018). According to the 
laboratory calculations performed with the MAIA designers (M. Morales 
unpublished observation), 0.7 mm correspond to 2.5° of the MAIA on the focal 
plane. The standard MAIA macular grid used in this study and in the majority of 
similar studies, consists of three concentric rings of 12 stimuli each, where the 
first ring has a diameter of 2°, corresponding to 0.56 mm on the focal plane. 
Therefore, to measure sensitivity in the central retinal thickness more accurately, 
a dedicated quantification of the 12 stimuli of the first MAIA inner grid may be 
advisable. 
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This assumption may be meaningful when the MP grid is centrally located on 
the anatomical fovea. In this study, it is observed the distance between both of 
the PRLs (initial and final) reported in the MAIA, where eyes with both PRLs 
far from each other are noted to have unstable fixation associated with non-
foveal vision. The results indicate that from 25% and up to 67% of our studied 
cases were associated with non-foveal vision in the different groups. These 
observations do not imply that the results from correlation in this study, as well 
as other reports in the literature which include MP are wrong. Rather, it is 
postulated that clinical studies analysing correlations between MP and central 
macular thickness, must ascertain that the MAIA grid is effectively centred on 
the fovea, and consider quantifying an eccentricity margin of error in patients 
with non-foveal function. 
 
Likewise, when analysing central retinal thickness from OCT data special care 
must be taken, specifically in cases where the PRL is slightly eccentric. In the 
present study we identified cases of patients with slightly eccentric fixation, 
where the OCT imaging system is wrongly centred over a non-foveal location, 
resulting in erroneous quantification of the central retinal thickness. (Figure 
6.17). 
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Patient from Anti-VGEF group showing the MAIA grid centred on the PRL 
located approximately 1° from the fovea. The OCT shows normal values on the 
central fovea, where in reality, the central fovea should’ve been reported with 
the abnormal values shown on the adjacent quadrants from the fovea. 
 
 
A significant finding in this study is that  fixation stability may be better 
correlated to post-treatment VA, and that retinal sensitivity and macular 
thickness are not always correlated. This reinforces the importance of including 
retinal function variables in macular treatment studies, as such variables may 
represent subclinical indicators, not anatomically perceived with OCT 
examinations. 
 
Although fixation indices showed a better correlation with VA than retinal 
sensitivity and thickness, it was observed that fixation stability, according to the 
Fujii classification (Fujii et al., 2002), have variable changes during follow-up 
visits. The interpretation of these findings is that, on the one hand, when 
pathologies affect the integrity of foveal photoreceptors, intravitreal injections 
therapy may not recover such cellular function. As such, patients who have 
Figure 6.17  OCT with eccentric fixation 
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developed unstable fixation in the course of their pathology, may remain with 
their unstable fixation even after intravitreal therapies. On the other hand, the 
Fujii classification of fixation stability, which states 3 fixation levels, may 
require revision, as important changes on the raw data related to both fixation 
indices (P1 and BCEA) within the relatively-stable and unstable classification 
were noted in this study. It is suggested that improving the classification of 
fixation stability from 3 levels to 5 levels, may provide better correlation of new 
fixation indices with VA, which may serve as better predictors of therapy 












7. Impact of dark adaptation time in 





Patients with age-related macular degeneration have particularly decreased 
vision in dim light conditions and require high ambient light in some settings 
(e.g. when reading). Such changes occur even at the early stages of AMD. 
Multiple retinal diseases are associated with rod photoreceptor functional 
impairment including rod-cone dystrophies (Lorenz et al., 2000), macular 
telangiectasia type 2 (Schmitz-Valckenberg et al., 2009), and retinitis 
pigmentosa (Arden et al., 1983). In earlier studies, some investigators have 
demonstrated that parafoveal rods, but not cones, decrease during the course of 
normal adulthood (Curcio et al., 1993). Moreover, they have hypothesised that 
early parafoveal loss of rods may be a subclinical sign in AMD, not yet visible 
in the fundus, whilst rod loss precedes cone loss in both exudative and 
nonexudative AMD (Curcio et al., 1996). Furthermore, psychophysical data in 
patients with early and late AMD have suggested that rod dysfunction exceeds 
cone dysfunction (Owsley et al., 2000). This observation of scotopic 
preceding/exceeding photopic sensitivity loss in individuals with AMD is 
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supported by histopathologic data that demonstrated a preferential vulnerability 
of rods (Curcio et al., 1993). 
 
The first commercially available device for automated dark-adapted perimetry 
was a modified first generation Humphrey Field Analyzer (Jacobson et al., 1986) 
(HFA, Carl Zeiss Meditec Inc., Dublin, CA, USA). Later, a few reports were 
generated on scotopic fundus controlled perimeter with a modified version of the 
Nidek MP-1 microperimeter, the MP-1S (Nidek Technologies, Padua, Italy) 
(Steinberg et al., 2015, Steinberg et al., 2016, Nebbioso et al., 2014, Crossland 
et al., 2011c, Salvatore et al., 2014). However, the dynamic range of the MP-1 
light stimuli (20 dB) is considered to be low and prone to ceiling and floor effects 
in both mesopic and scotopic examinations (Steinberg et al., 2015, Crossland et 
al., 2011c, Midena et al., 2007). 
 
Recently a modified version of the MAIA microperimeter, the Scotopic-MAIA 
(S-MAIA), became available allowing for mesopic light threshold sensitivity 
(LTS) testing with achromatic stimuli projection, as well as scotopic testing with 
two chromatic stimuli, cyan (505 nm) and/or red (627 nm). While the scotopic 
cyan (blue) testing is intended to be largely derived from rod photoreceptor-
mediated function, also excluding S-cone activity, the scotopic red would be 
more influenced by cone-mediated function, rather reflecting a mixture of both 
rod- and cone-mediated responses (Pfau et al., 2017a). Scotopic examinations 
must be performed on patient’s dark-adapted conditions. One challenge for the 
practical application of scotopic microperimetry in clinical settings is the time 
taken for the patient to dark adapt, which is in addition to the testing time. It has 
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been reported that fatigue during long psychophysical examinations may reduce 
patent’s capacity to fixate (Morales et al., 2013). As such, the aggregation time 
of dark adaptation and scotopic microperimetry testing should be kept as low as 
possible. 
 
We conducted a study to investigate the potential impact of different dark 
adaptation times on scotopic retinal LTS as well as assessing the test-retest 
repeatability of the S-MAIA for each dark adaptation time and explored the 





This was an observational, descriptive, study on individuals with no known 
ocular pathologies from the University of Belfast campus. The study had 
institutional board approval from the research ethics committee of The Queens 
University Belfast, School of Medicine Dentistry & Biomedical Sciences, 
Belfast, U.K. Informed consent was obtained from all participants, and the study 
met the tenets of the Declaration of Helsinki.  
 
Participants 
Twenty-four adult, medical students and staff colleagues (mean age = 32.3 
years), with best corrected visual acuity (VA) of LogMAR 0.1 (ETDRS) or 
better, were recruited. Inclusion criteria for this study were as follows: adult age 
above 21 and below 80 years, participants with normal vision, no limitation to 
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race, ethnicity, or sex; and willingness to rest in absolute darkness for an 
approximately time of one hour.  
 
The exclusion criteria included any diagnosis of ocular disease, opaque ocular 
media, diagnosis of squint, or any other condition that would cause any kind of 
fixation instability, refractive error higher than 6 or lower than -6 diopters, and 
people with known nyctophobia symptoms. 
 
Equipment and Procedures 
The basic design of the MAIA device has been described in previous chapters. 
In brief, it is a mesopic test which utilizes a confocal SLO system with a 
wavelength of 850 nm to image the retina. Retinal sensitivity is assessed with 
Goldmann size 3 class achromatic (white) stimuli, projected through an LED 
system within the central visual field. The retinal land mark eye tracker aids test-
retest stimuli projection over the same base-line retinal area. The visual target 
used for fixation during testing is a 645 nm red ring with 1° diameter 
superimposed over 4 asb (127 cd/m2) background display. The mesopic MAIA 
examination is a 4–2 full threshold staircase projection strategy with maximum 
stimuli luminance of 1,000 asb and 36 dB dynamic range. The S-MAIA is an 
adaptation of the standard (mesopic) MAIA which allows for scotopic LTS 
testing on patients under dark adaption visual conditions. For that purpose, all 
internal light sources were eliminated from the device, two colour LED systems 
were added and the SLO power was significantly reduced during testing with 
absent background luminosity. The scotopic stimuli projections are available in 
two different wavelengths, 505nm (cyan) and 627nm (red). The maximum 
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stimuli luminance is 0.8 asb, with a dynamic range of 20 dB (S-MAIA software 
version 2.2.0-2016). In this study, a testing grid with 45 stimuli was used. The 
stimuli grid distribution (Figure 7.1) contained 1 central stimulus, and 5 stimuli 
concentric rings separated from the centre at 1° (4 stimuli), 2.5° (8 stimuli), 4° 
(12 stimuli), 6° (12 stimuli) and 10° (8 stimuli). Examinations were performed 





S-MAIA stimuli distribution diagram used in this study (left) with the fundus 
related light threshold sensitivity (LTS) output.  
 
 
In both examination modes (mesopic and scotopic), the MAIA start testing with 
4 paracentral stimuli, corresponding to the central stimulus of each quadrant. 
These 4 threshold values are then used to adjust the initial brightness levels for 
measuring the remaining test loci in each of the corresponding quadrants. For 
mesopic mode, the testing sensitivity started with a level of 2 dB brighter of the 
respective initial threshold value using a 4–2 dB full-threshold strategy. For 
Figure 7.1  Scotopic MAIA grid 
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scotopic testing, the testing sensitivity started with a level of 2 dB dimmer than 
the respective initial threshold, particularly to avoid bleaching, and using a 2–1 
dB full threshold strategy. These testing settings were not modifiable in the 
device (software version 2.2.0-2016). It is noteworthy that after our study report, 
the company Centervue modified the S-MAIA dynamic range from 20 dB to 36 
dB in subsequent software versions. 
 
Two scotopic microperimetry sessions were performed within a maximum 
separation of one week (7 days). In the first session, measurement of refractive 
error was carried out with an auto-refractometer (ACCUREF K-900, Shin-
Nippon, Japan); the eye with the least refractive error in terms of spherical 
equivalent was chosen as the study eye. As a microperimetry training test, the 
participant performed a mesopic supra-threshold examination, known as the fast 
exam in the MAIA, with the sole purpose to familiarise each participant with the 
examination task. After that, scotopic microperimetry examinations were 
performed in 3 different dark-adapted time conditions: 10, 20 and 30 minutes. 
To reverse the dark adaptation between tests, a 10-minute break with room lights 
on (luminance 0,10lux) was done. During the dark adaptation period, 
participants remained in the dark testing room (luminance ≤ 001 lux). This 
luminance level has been used in other studies as well (Pfau et al., 2017a). Study 
participants were instructed to keep their eyes open during the dark adaptation 
period. Two consecutive scotopic examinations were performed on each session, 
first with the cyan (C ) and immediately after with the red (R) stimuli. Test 
reliability was assessed by measuring the frequency of false-positive responses 
(measured by presentation of a suprathreshold stimuli to the optic nerve head). 
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Participants with a false positive rate greater than 33.3% in any of the tests were 
excluded from the analysis. 
 
Statistical Analysis 
Statistical analysis was carried out with SPSS version 22 (IBM Corp. Released 
2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM 
Corp.). All variables were assessed for normality using the Shapiro-Wilk test 
and transformed if necessary. For comparison between thresholds of the three 
dark adaptation times the results from the first session only were used in the 
analysis.  The means produced from each dark adaptation interval, for each 
stimulus (C and R) and their difference (C-R), were compared with one-way 
ANOVA. Repeatability was assessed producing Bland-Altman plots, whilst 
reliability using intra-class correlation coefficient (ICC). The categorization and 
interpretation of ICC was based on published guidelines. These suggest that ICC 
values <0.5 indicate poor reliability, values between 0.5 to 0.75 indicate 
moderate, values between 0.75 to 0.9 good and finally values >0.9 indicate 
excellent reliability (Koo and Li, 2016). The extent of a learning effect was 





Twenty-four persons agreed to participate; two were unable to attend the second 
session and were excluded from the final analysis. Furthermore, two other 
participants could not finish one of the tests and were also excluded. This 
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resulted in a sample of 20 individuals with a total of six scotopic sessions each. 
Of these, 5 were males and 15 females. Mean age in the studied sample was 
32.30 years old ± 10.50 SD. The mean refractive error in terms of spherical 
equivalent was -1.22 diopters ± 1.86 SD.  
 
 
Effect of Dark Adaptation time on Scotopic 
Sensitivity  
 
For the cyan stimuli, we found no significant difference between 20 minutes of 
dark adaptation when compared to the 10 minutes (p=0.08) or the 30 minutes 
intervals (p=0.18). Instead, a significant difference was found when the 30 
minutes period of dark adaptation was compared to the 10 minutes interval 
(p=<0.01). For the red stimulus on the other hand, there was no significant 
difference between any of the adaptation times. Finally, when assessing the 
differential test (C-R), both 20 and 30 minutes were significantly different when 
compared to the 10 minutes adaptation time (p=0.02, 20’ and p=<0.01, 30’). 
When the 20- and 30-minutes intervals were compared with each other, 









Assessment of the impact of dark adaptation time on scotopic retinal threshold assessed with 





The Bland-Altman test, plots the difference of the two sessions (Visit 1 – Visit 
2) against the mean (Visit 1 + Visit 2 / 2). The 95% levels of agreement for the 
C stimuli ranged from -2.70 to 2.19 with a mean difference of -0.25. For the R 
stimuli -2.27 to 1.75 with a mean difference of -0.26, whilst for the difference 
(C-R), the 95% levels of agreement ranged from -2.14 to 2.16 with a mean of 
Table 7.1  Dark adaptation time 
118 | P a g e  
 
0.01 (Fig. 7.2). The widest limits of agreement were found in the scotopic C test. 
On the other hand, most outliers were found on the scotopic R test as compared 
to the C, or C-R average threshold values. However, in general, most of the 
values lie within the 95% confidence limits despite the presence of a few outliers. 
The finding of outliers though, which indicate a degree of variability, is one 
which exists in perimetry testing (Wong et al., 2017b, Wong et al., 2017a, Wu 
et al., 2013b). 
 
 
Bland-Altman Plots for Cyan (top), Red (middle) and Cyan – Red average threshold(bottom). 
The solid lines represent the mean for each measurement while the dashed lines correspond to 
the 95% upper and lower levels of agreement. On the x-axis the mean average threshold for each 




In order to further assess the reliability of the device, we calculated the intraclass 
correlation coefficient (ICC) analysis (Table 7.2). The highest ICC was found 
Figure 7.2  Bland-Altman Plots for Scotopic testing 
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for the cyan stimulus (0.90, p<0.01) approaching an excellent test-retest 
reliability. The red stimulus on the other hand, showed moderate ICC (0.74, 
p<0.01). The difference of both stimuli, C-R was also found good with an ICC 
0.86 and a p<0.01. The categorization of ICC interpretation was based on 




Intraclass Correlation test (ICC) between examination types. Values <0.5 indicate poor 




The paired samples t-tests gave no statistically significant differences (Table 7.3) 
between study visits. However, the only tests that appeared to show a learning 
effect were the differences between the two 10’ sessions with the C (p=0.03) and 
R (p=0.03) stimuli. Repeated measures ANOVA, after Bonferroni adjustment, 
showed no significant learning effect present for the C stimulus (p=0.12) or the 
C-R (p=0.94), with a borderline suggestion from the R results (p=0.05). 
 
Table 7.2  Intraclass correlation scotopic test 




T-test evaluation for the three different dark adaptation times on the scotopic-cyan and scotopic-






This study provides data on the impact of dark adaptation time on scotopic retinal 
sensitivity as obtained with the S-MAIA, the repeatability and reliability of the 
measurements, and the potential presence of a learning effect. 
 
The results indicated that careful thought was required when deciding on the 
correct dark adaption period in order to obtain stable threshold results. The data 
suggest that for the C stimulus, a 30 minutes interval in the dark, produced 
significant differences when compared with the 10 minutes time, but only a trend 
to significance when is compared to the 20 minutes adaptation time. For the R 
stimulus on the other hand, dark adaptation interval did not appear to impact 
sensitivity thresholds. However, when the results are taken in their entirety, we 
observed that for the majority of cases there was no difference between the 20’ 
and 30’ threshold values. It is thus suggested that a time selection of a minimum 
Table 7.3  T-test for dark-adaptation time 
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of 30’ of dark adaptation would favour the C-R results a significant difference. 
Confirmation of this finding would require a larger sample size. 
 
The duplex theory of vision states that for luminance levels above 0.03 cd/m2, 
the cone system mediates vision. For luminance levels below that point, rods 
take over, while the range in which these two mechanisms are working together, 
is the mesopic vision range (Weale, 1961). Rod peak spectral sensitivity is 
around 500nm (Kelber et al., 2017), with the C stimulus having a wavelength 
close to that (λ=505nm) and the topography of rod photoreceptors having been 
reported (Curcio et al., 1990), our findings come in agreement with Pfau (Pfau 
et al., 2017a), who reported that the C well reflects rod-mediated visual function. 
On their point-wise mean sensitivity analysis, these authors observed that the 
highest mean was at an eccentricity of 7o from the fovea. This pattern of 
sensitivity reaching peak values with the C stimulus at a diameter 5o to 7o was 
observed in our study as well. Future work could explore if the impact of dark 
adaption time differed with retinal eccentricity.  
 
The repeatability test results showed good agreement between measurements. In 
both scotopic tests, C and R, most points fell within the 95% levels of agreement. 
The same occurred for their difference (C-R). An interpretation of the few 
observed outliers is that a degree of variance occurred. Most outliers were found 
in the R test (3 in total) when compared to C (2 in total). 
The results for ICC suggest that the device is reliable to use as it provides high 
ICC values 0.90 for C, 0.74 for R and 0.86 for C-R respectively. Pfau et al also 
suggested that the scotopic device is repeatable and reliable to use in both, 
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healthy and persons with macular diseases (Pfau et al., 2017a, Pfau et al., 2017b). 
Results for repeatability and reliability of the standard MAIA, have been 
reported for individuals in normal retinal health, in patients with different ocular 
diseases and in children (Molina-Martin et al., 2015, Jones et al., 2016, Wu et 
al., 2015, Wong et al., 2017b). 
 
In agreement with other studies, data from the current study suggests that there 
is no significant learning effect on the basis of repeated measures ANOVA with 
the Bonferroni adjustment applied. The absence of a learning effect for the S-
MAIA has been reported previously by other authors (Pfau et al., 2017a). 
However, this is contrary to the results obtained by Wu et al., who reported a 
learning effect in the standard MAIA device and, therefore, mesopic testing 
conditions, and recommended discarding the results from the first session (Wu 
et al., 2013b). It is hypothesized that the use of a training test (fast examination) 
may have improved repeatability. However, results from the current study may 
be limited as no randomization was applied in the investigations. 
 
A limitation of this study is the small sample size included, and that analysis 
could have been extended to measure the effect of time of dark adaptation in 
different retinal eccentricities. On the other hand, our main focus was to use three 
different times of dark adaptation to obtain our results, compared to previous 
studies that used only one-time interval. The previous study also reported short 
term repeatability with both testing sessions occurring on the same day, whereas 
this study had a one week window (Pfau et al., 2017a). 
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In summary, this study is the first to evaluate the impact of dark adaptation time 
on scotopic retinal sensitivity measured using scotopic microperimetry. The 
results suggest that the time of dark adaptation did have an impact on the 
outcome measure. If this is to be estimated from the cyan stimulus, which well 
reflects rod function, a period of 30 minutes dark adaptation is preferable. If 
scotopic sensitivity is to be estimated from the difference C-R, the minimum 
dark adaptation time required, could be slightly reduced to 20 minutes. 
Additionally, this study provides data which suggests that the MAIA produces 
repeatable and reliable measurements with no evidence of a significant learning 












8. Rehabilitation of eccentric vision with 





Motor neuro-rehabilitation aims to improve patient’s functional abilities, 
replacing skills that have been lost fully or partially. A general neuro-
rehabilitation mechanism of action is the potentiation of a group of latent 
neuronal connections that are utilized repeatedly during challenging behavioural 
practice. The repeated and persistent practice, over several weeks, of a 
challenging movement facilitates neural synapsis, which may result in lasting 
physiological changes in motor neural networks (Lang et al., 2015, Nudo, 2013). 
 
The motor skills acquisition process may be described in distinct phases (Nudo, 
2013, Doyon and Benali, 2005) from the early to  consolidation stages, when the 
newly acquired skill is performed with minimal cognitive resources. The final 
stage is defined as when the performance can be executed after long delays 
between training sessions (Doyon and Benali, 2005). Although the literature on 
neurological rehabilitation is vast, there are numerous and inconsistent 
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parameters of intensity, frequency and therapy duration related to induced 
movement studies (Lang et al., 2015, Gee et al., 2018). 
 
The fovea is responsible for detailed vision and fixation. Patients with central 
vision loss attempt fixation with an eccentric retinal zone known as the Preferred 
Retinal Locus (PRL) (Crossland et al., 2011b). As mentioned in previous 
chapters macular function can  be assessed with  microperimetry (MP) by means 
of light threshold sensitivity (LTS), fixation stability (FS) and the PRL which 
can be plotted as a cloud of fixation points over a reference retinal image 
(Morales et al., 2013). FS in microperimetry is classified as stable, relatively 
unstable or unstable (Fujii et al., 2002). The MAIA microperimeter scores FS 
with different indexes; the most representative are P1 and the bivariate contour 
ellipse area (BCEA) with proportional values of 95% (Morales et al., 2016). P1 
describes the amount of retinal displacement occurring within 1° from an initial 
reference point, whilst BCEA describes 95 % of retinal loci used during fixation 
attempt. 
 
Eyes with eccentric fixation regularly demonstrate unstable FS with associated 
low vision. However, it has been reported that FS can be improved with 
oculomotor exercises known as biofeedback fixation training (BFT) 
(Markowitz, 2006, Vingolo et al., 2007, Tarita-Nistor et al., 2009b, Amore et al., 
2013, Morales et al., 2015, Morales et al., 2013), a task-oriented behavioural 
therapy, which according to some authors may drive neural plasticity changes in 
the visual system (Tarita-Nistor et al., 2009b, Chung, 2011). BFT consists of 
asking patients to perform ocular movements towards a specific direction, 
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attempting to align a selected retinal locus with a visual target. This locus is 
known as the fixation training target. Biofeedback audio signals (beep sounds) 
aid patients during the oculomotor task by increasing the auditory frequency as 
the training target approaches the desired alignment. To be of value, the training 
target should have better functional characteristics than the PRL previously used 
by the eye with unstable fixation. However, the selection of this training target 
has not been described previously.  
  
The index case for this study was published as ‘Bilateral eccentric vision training 
on pseudovitelliform dystrophy with microperimetry biofeedback’ in 2015 
(Morales et al., 2015), which allowed a methodology for eccentric biofeedback 
to be developed. 
 
In this study we describe a methodology for selecting the best fixation training 
target, with the aim of improving eccentric fixation through BFT with MP in 





This was a prospective, consecutive, case series study of a cohort of patients with 
irreversible bilateral central vision loss, poor FS and best corrected visual acuity 
(VA) of 0.3 LogMAR or worse, who performed and completed BFT sessions 
with the MAIA MP. The study included participants from the Low Vision and 
the Macular Clinics of the Queen’s Medical Centre, Nottingham (U.K.) and were 
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recruited from January 2013 to June 2017. Local ethical approval and written 
informed consent was obtained from all participants, and the study met the tenets 
of the Declaration of Helsinki.  
 
Participants 
Ninety patients (mean age = 67.5 years), with bilateral central vision loss 
secondary to different pathologies affecting the macula, with unstable fixation 
and best corrected visual acuity (VA) of LogMAR 0.3 (ETDRS) or worse, were 
recruited.  
 
Inclusion criteria for this study were as follows: adult age above 21 and below 
80 years, patients with bilateral central vision loss, geographic atrophy area with 
scotoma bigger than 1 disk size and smaller than 5 disk sizes, stable pathology 
with at least 6 months from last anti-VEGF injection if any, patients willing to 
improve reading abilities. There was no limitation to race, ethnicity, or sex. The 
exclusion criteria were: mild to severe cataract (over grade 2) or other opaque 
optical media, active macular oedema, uncooperative patient, or non-English 
speaker. 
 
Equipment and Procedures 
Patients were scheduled for BFT using the MAIA MP. The eye with the better 
VA for each participant was selected for this study. If both eyes had equal VA 
the eye with better FS was selected. Patients were, alternately divided into 2 
different groups. In group A (mean age 64.7 ± 22 years), the retinal locus for 
BFT was set on the baseline patient’s spontaneous PRL, assessed with the MAIA 
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Standard-Macula-Test (10°, 37 stimuli). In group B (mean age 70.4 ± 14 years), 
BFT was performed on the locus with the best functional characteristics. To 
determine this locus, two custom MAIA exams were performed: A) the “Low-
Vision-Assessment” grid-test (30°, 83 stimuli) with the 4-levels-fixed projection 
strategy, which scores retinal sensitivity as “good” (25dB), “relatively good” 
(15dB), “relatively poor” (5dB), “poor” (0dB) and “scotoma” (<0 dB); and B) 
the “Fixation-Training-Target” grid-test (7°x5°, 35 stimuli) with the 4-2 
projection strategy. The first one, (A), was centred on the estimated foveal 
location, or on the patient’s PRL in cases of GA larger than 3 times the optic 
nerve head size (ONH). The Low-Vision-Assessment grid output was used to 
identify retinal loci with at least 2 consecutive stimuli, distributed horizontally, 
showing “good” or “relatively-good” light sensitivity, and served as a reference 
to centre the Fixation-Training-Target grid, prioritizing the superior retina 
(inferior visual field) and the smaller distance from the anatomical fovea. The 
second custom test, (B), was used to select the target locus for BFT. This locus 
was set in the centre of the two adjacent stimuli with highest light sensitivity, 
and lowest distance from both the anatomical fovea and the baseline PRL (Figure 
8.1). 
 
Adapting the training frequency reported in the literature (Deruaz et al., 2006, 
Vingolo et al., 2007, Tarita-Nistor et al., 2009b, Amore et al., 2013, Verboschi 
et al., 2013), and with the scope to reach consolidation and retention therapeutic 
stages, we performed 2 sets of 12 weekly training sessions separated by a 3 
month period of no training. Each session lasted 10 minutes. BFT consisted of 
asking patients to move their gaze slightly towards the training locus. The 
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auditory signal increased in frequency as the desired eye movement reached the 
target. Patients were advised to remember the gaze movement performed during 
the training sessions, and to try to reproduce the same movement in their daily 
life when attempting to steadily see a visual target. 
 
The final results were assessed at 2 weeks after completing BFT sessions. 
Primary outcomes were classification of FS, fixation indices P1 and 
BCEA@95%, VA, and reading speed (IReST) (Trauzettel-Klosinski and Dietz, 
2012). FS values after the first training session, and after 6 months from baseline, 
were also recorded. Secondary outcomes were mean light sensitivity. The 
anatomical location and the visual field correspondence of the PRL were also 
annotated. 
 
Microperimetry exam grids: A) “Low-Vision-Assessment” grid centred on patient’s PRL with 
the 4-Levels-Fixed projection strategy, showing five different dB levels of retinal sensitivity: 
green = 25dB, yellow = 15dB, red = 5 dB, purple = 0dB, black = <0 dB (scotoma). B) “Fixation-
Training-Target” grid with the 4-2 projection strategy, used to select the locus with highest 
retinal sensitivity for subsequent BFT sessions. 
 
Figure 8.1  Low vision MAIA grids 
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Statistical Analysis 
Statistical analysis (GraphPadPrism_7.04) included standard errors, 95% 
confidence, interquartile intervals and robust regression outlier removal. 
Assuming a non-parametric distribution, a one-tailed Mann-Whitney test was 
applied to compare outcomes between baseline and the last training sessions for 
each group, and between groups with a significant difference of P<0.05. 






Twenty-three patients withdrew from the study before completing all BFT 
sessions either because they did not notice improvement in vision or could not 
attend regularly for training/assessment. These withdrawals were excluded from 
analysis. A total of 67 patients completed the study; 30 had Geographic Atrophy 
(GA), 19 moderate dry AMD, 9 Best’s Disease, 6 Myopic Macular Degeneration 
and 3 chronic Central Serous Retinopathy (CSR). Group A included 20 females 
and 8 males, whilst group B had 27 females and 12 males. Mean central scotoma 
sizes were 5.4° ± 3.8° and 5.7° ± 4.5° for groups A and B respectively. 
 
At baseline, the FS classification in group A was unstable in 18 subjects (64%), 
relatively unstable in 9 (32%), and stable in 1 (4%). At the end of therapy, 16 
subjects (57%) were classified as unstable, 11 (39%) as relatively unstable, and 
1 (4%) as stable. In group B, the baseline classification was unstable in 19 (49%) 
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subjects, relatively unstable in 19 (49%), and stable in 1 (2%). At therapy end, 
11 subjects (28%) were classified as unstable, 16 (41%) as relatively unstable, 
and 12 (31%) as stable (Figure 8.2). 
 
 
Classification of fixation stability on baseline (BL) and end of biofeedback training for both 
groups A & B. 
 
In group A, the mean FS index P1(%) was 32 ± 19 at baseline, 26 ± 18 after the 
first BFT session, 34 ± 22 at six months, and 35 ± 23 at the end of therapy. In 
group B, the mean P1 was 40 ± 24 at base-line, 27 ± 20 after the first BFT, 48 ± 
29 after six months, and 55 ± 29 at therapy end (Figure. 8.3A).  
 
The mean area (deg2) of BCEA@95 in group A was 38 ± 23 at baseline, 51 ± 47 
after the first BFT, 33 ± 22 at six months, and 32 ± 25 at study end. In group B, 
the mean area was 39 ± 40 at baseline, 64 ± 70 at first BFT, 30 ± 31 at six months, 
and 19 ± 18 at therapy end (Figure. 8.3B).  
Figure 8.2  Classification of FS in LV group 
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The FS index P1 did not improve in 50% of subjects in group A, and 18% in 
group B. Similarly, 35% of group A subjects did not improve in BCEA@95%, 
compared to 10% of those from group B. 
 
 
Box-and-whisker plot showing quartile distribution and mean data of fixation 
index P1 (A) and BCEA@95% (B) at baseline (BL), after the first BFT session, 
6 months after first treatment and at the end of all BFT sessions (EBFT). 
 
Visual acuity (LogMAR) in group A ranged from 0.4 to 1.9 at baseline and 0.3 
to 2.0 at the end of therapy, whilst for group B the range was from 0.3 to 2.0 at 
baseline and 0.1 to 2.0 at the end of therapy. The mean VA in group A improved 
from 1.0 ± 0.48 to 0.86 ± 0.53 at therapy, whilst for group B the improvement 
was from 1.0 ± 0.51 to 0.84 ± 0.49. In group A the improvement was observed 
in 16 (57%) subjects, whilst for group B the improvement was found in 26 (67%) 
participants. The VA was unchanged in 4 (14%) subjects in group A and 10 
(25%) from group B, whilst a decrease in VA was seen in 8 (29%) participants 
from group A and 3 (8%) from group B.  The mean reading speed (wpm) 
improved from 56 ± 30 to 58 ± 32 in group A, and from 63 ± 36 to 89 ± 46 in 
group B (Figure 8.4). 
Figure 8.3  FS analysis over time 
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Treatment efficacy (baseline vs therapy end) showed no significant difference in 
any of the studied variables in group A, as demonstrated with the one-tailed 
Mann-Whitney test (Table 1A). In contrast, differences were found in all group 
B variables except on light threshold sensitivity (LTS) (Table 1B). When 
comparing final outcomes between groups, a significant difference in all 
parameters was found, except for VA (Table 1C). 
 
 
Example of a group B patient, showing the cloud of fixation points with different PRL location 
and improvement of fixation stability from baseline (A) to end of biofeedback training (B). 
Fixation improved from unstable to relatively unstable, and visual acuity from 1.03 to 0.8 
LogMAR. 
 
Baseline FS indexes in group A showed moderate correlation (0.50 < r < 0.70) 
with their final FS values and scotoma extension. However, high correlation (r 
> 0.7) was found with final reading speed. In group B, base-line FS indexes were 
highly correlated (r > 0.7) with final FS values, whilst moderately correlated 
with final VA and reading speed. FS outcomes demonstrated negligible 
Figure 8.4  PRL after fixation training 
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correlation with scotoma size (r = 0.2), whilst low dependence with the trained 
location (r = 0.3) was found. Final VA showed better correlation with baseline 
FS in group B (r = 0.4) than group A (r = 0.2). Final reading speed was better 
correlated with base line FS (P1) in group A (r = 0.7) than group B (r = 0.5). 
Low correlation was found (r < 0.3) in both groups between functional outcomes 
and patient’s age. A week correlation was found (r < 0.3) after performing a 





Mann-Whitney Test of a) Baseline vs Therapy-end for group A. b) Baseline vs Therapy-end for 




Table 8.1  Final intergroup comparisons 




Although task-specific training to enhance motor representations has been 
reported for several decades (Lang et al., 2015), only a few authors have 
demonstrated FS improvement in patients with foveal impairment using 
biofeedback and microperimetry (Morales et al., 2015, Verdina et al., 2013, 
Verboschi et al., 2013, Amore et al., 2013, Tarita-Nistor et al., 2009b, Tarita-
Nistor et al., 2009a, Vingolo et al., 2007, Markowitz, 2006, Deruaz et al., 2006, 
Chung, 2011). Furthermore, detailed methodologies adopted to define the best 
functional retinal locus for such training have not been fully described. 
 
Ramirez et al. (Ramirez Estudillo et al., 2017). following our suggestions, 
demonstrated the effectiveness of BFT one week after completion of therapy, 
whilst Ratra et al. (Ratra et al., 2018), recently demonstrated in a small number 
of patients that the BFT effect can be maintained for up to six months with slight 
reduction in fixation stability. Our study demonstrated a similar reduction, 
suggesting that such visual training should be attempted over longer periods in 
order to achieve maximum results. 
 
Our study adds additional credence to the notion that fixation in patients with 
eccentric vision can be improved through biofeedback therapy. Nudo (Nudo, 
2013) suggested that without behavioural training, plasticity in spared motor 
areas, which occurs spontaneously, largely reflects the development of 
compensatory motor patterns rather than patterns of true recovery. Our findings 
highlight the concept that localized fixation training may enhance plasticity more 
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efficiently than when training is performed on the PRL which was spontaneously 
developed by the individual after the loss of foveal function. 
 
BFT is reported to be dependent on the location, with the highest retinal 
sensitivity in small central scotomata (Ueda-Consolvo et al., 2015). However, 
we explored the possibility of standardised BFT in cases with any central 
scotoma size. The BFT theory is based on neuro-plasticity, where healthy neural 
sensors are frequently stimulated. When retina photoreceptors and ganglion cells 
are healthy, microperimetry outcomes demonstrate high light threshold 
sensitivity values. For this reason, our first selection criteria to define the best 
locus for BFT is a retinal location with good light sensitivity.  
 
Detailed vision is performed with high packing density of cone photoreceptors. 
Its density peak, located at the foveal centre, decreases rapidly within the central 
2mm, with a gradual decrease further away from the fovea (Song et al., 2011). 
Subjects with healthy vision perform fixation within the central 2°, as 
demonstrated with the MAIA (Morales et al., 2016). Consequently, the assumed 
correlation between density of cones and fixation abilities is valid. Recent 
studies confirmed photoreceptor’s density decreases at 1°, 2°, 4 and 6° of 
eccentricity, showing a homogenous drop in each of the four retinal meridians, 
and high agreement between nasal and temporal locations (Song et al., 2011, 
Lombardo et al., 2013). These results suggest that patients may have similar 
anatomical visual capabilities at any retinal meridian with eccentric equidistance 
from the fovea. In light of these associations, the second selection criterion for 
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the BFT locus corresponds to an area located closer to the anatomical fovea 
without discrimination of the retinal meridian.  
 
Previous studies suggest that reading with eccentric viewing may be more 
efficient if the PRL is located on the left hemisphere and the lower visual 
field.(Fletcher and Schuchard, 1997, Nilsson et al., 2003, Frennesson and 
Nilsson, 2007) These observations reinforced our third BFT locus selection 
criterion, suggesting the predilection on the left and/or superior side of the 
central scotoma whenever good light sensitivity is present. 
 
Finally, it is well known that PRL positions may also depend on the visual task. 
In the western world, reading is performed from left to right. Reading tasks 
involve eye fixation and saccadic movements following a horizontal path. For 
that reason, our methodology locates the training location in the middle of a 
horizontal line, with at least 2 adjacent stimuli with good sensitivity.  
 
Our investigation contributes to the literature with a thorough BFT analysis, and 
scope to understand the rationale behind the selection process of an effective 
retinal locus useful during eccentric fixation training in patients with foveal 
function loss. This suggested BFT methodology is summarised as follows: 
 
1. Perform the “Low-Vision-Assessment” grid-test with the 4-levels-fixed 
projection strategy centred on the anatomical foveal, or on the patient’s baseline 
PRL in eyes with Geographic Atrophy larger than 3 times the optic nerve head 
(ONH). 
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2. Identify loci with at least 2 consecutive stimuli, distributed horizontally, of 
good or relatively-good threshold sensitivity (GTS). 
3. Perform the “Fixation-Training-Target” grid-test with the 4-2 projection 
strategy. Centre the grid on the GTS loci. If there are more than 1 GTS options, 
prioritize the smaller distance to the fovea on either the superior retina or the left 
visual field with lower distance from the base-line PRLs. 
4. Use the “Fixation-Training-Target” grid outcomes to select the final trained 
retinal locus to perform BFT. This locus should be set in the centre of the 2 
highest horizontal adjacent threshold stimuli. 
5. Perform 10-minute BFT sessions over the selected training target on a weekly 
basis for 12 weeks. After a resting period of 3 months, perform a new set of 12 
weekly BFT sessions to aid visual plasticity consolidation. 
 
To conclude, in this study we have described a methodology for BFT with 
microperimetry, with the scope to improve eccentric vision through better 
fixation control. Further studies are needed to validate the effectiveness of this 
methodology in everyday visual tasks, such as reading and other visuomotor 
activities. Of paramount importance is an investigation of the different motor-
sequence adaptation stages during BFT, in particular, the recognition of the 
consolidation and automatic stages, as these may be the key to optimising 
frequency and duration for individual therapeutic strategies, as well as to 
understanding whether long-term plasticity changes are achievable, and 
retainable. 
  




9. Summary and recommendations. 
 
 
9.1 General Discussion 
 
The main objective of this research study was to analyse retinal functional 
characteristics with a MP in common macular diseases, including AMD, and 
determine its usefulness in the monitoring of disease progression, treatment 
outcomes, and visual rehabilitation, with the purpose of evaluating its benefits 
in the everyday clinical practice and propose a standardisation of use. In 
principle, the studies (with their findings) included in this thesis should allow 
better understanding of retinal function, as described by MP systems, and 
complement existing standard eyecare tests of VA (functional) and OCT 
(structural) analysis, aiming to predict better prognosis for patients with different 
macular pathologies. 
 
The study was divided in 2 main sections: monitoring of macular diseases and 
fixation training for eccentric visual rehabilitation. 
a) MP in the monitoring of macular diseases. This section included observation 
of pathologies commonly affecting the central vision and its related intravitreal 
therapies such as anti-VEGF for nvAMD, DMO and MO secondary to RVO 
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treated with anti-VEGF or dexamethasone implants and ocriplasmin for 
symptomatic VMT with or without early macular hole.   
b) MP fixation training for eccentric visual rehabilitation. This section included 
observation of functional visual outcomes in low vision patients with bilateral 
central vision loss secondary to macular pathologies such as, GA in AMD, 
Stargardts disease and vitelliform dystrophies, who attended several sessions of 
eccentric fixation training over a functional preferred retinal locus methodically 
selected with MP. 
 
In chapter 2, “Materials”, a general review of the differences between standard 
automated perimetry (SAP) and microperimetry (MP) was included, with a 
detailed explanation of the MAIA MP. The concepts of preferred retinal locus, 
fixation stability and biofeedback fixation training, were carefully described. An 
introduction of Scotopic MP and a general MP clinical review was also part of 
this section. In addition, a review of the Topcon OCT and the international 
reading speed test (IReST) were included. This chapter, as well as the preceding 
one (General Introduction and Rationale), provided useful background 
information that served as a starting point for the present research project. In 
particular, the anatomical, and clinical features, as well as the investigative 
instruments of the retina and macular pathologies affecting central vision are 
reviewed. 
 
Clinical studies including MP normally describe outcomes related to retinal light 
threshold sensitivity, whilst only a minority of MP scientific publications refer 
to fixation stability outcomes, which are mainly related to visual rehabilitation 
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training where fixation is a descriptive parameter of visual improvement. MP 
systems currently use different approaches to measure FS, namely P1, P2 and 
the bivariate contour ellipse area (BCEA), which describe an elliptical area 
encompassing a given proportion of the fixation points dataset (Crossland et al., 
2004). The P1 and P2 indices are used to classify fixation as stable, relatively-
unstable, and unstable. However, there was no a reference database available for 
any of the BCEA indices. For that reason, chapter 4 is dedicated to a study 
designed to determine normative data for such indices. This study included 
observations on 358 participants aged from 19 to 86 years, and described normal 
values of BCEA indices and their correlations with subject’s age and P1 and P2 
indices. 
 
The preferred retinal locus in microperimetry is described as the graphic 
representation of a cloud of fixation points plotted as a result of the retina 
movement during threshold examination. Chapter 5 reviewed the concept of the 
PRL_initial (i) and PRL_final (f) unique in the MAIA.  
These two PRLs are the barycenter reference point of such cloud of fixation 
points, but calculated in two different examination times, in the first 10 seconds 
of the test, before the projection of light stimuli, and at the time when all light 
stimuli were tested (around 6 minutes for the MAIA standard macula grid). The 
PRLi is used by the MAIA to center the grid map to be tested. The study of 65 
eyes from forty-one patients, correlated the distance between both PRLs with 
fixation stability and visual acuity, demonstrating that both VA and FS tend to 
decrease as the distance between PRLi and PRLf increases. The results suggested 
that eyes with both PRLi and PRLf close to each other are noted to have stable 
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fixation located over the fovea centralis, whilst eyes with PRLi and PRLf far 
from each other (higher than 0.8°) are noted to have unstable fixation located 
eccentrically from the fovea. This information was used on chapter 6 to 
objectively identify foveal or non-foveal fixation on patients with macular 
pathologies. This investigation was accepted for publication as the first 
manuscript describing such characteristics of PRL_initial (i) and PRL_final (f). 
 
In Chapter 6 a thorough analysis of MP outcomes was conducted and correlated 
with OCT central retinal thickness and visual acuity. A total of 74 patients 
attending the macula clinic for intravitreal therapy were included in the analysis. 
Patients were divided in 4 groups according to the intravitreal treatment. Group 
1, Anti-vascular endothelial growth factor (anti-VEGF) drugs for wet 
(exudative) age-related macular degeneration (AMD). Group 2, Intravitreal 
dexamethasone implant for the treatment of diabetic macular oedema (DMO). 
Group 3, Intravitreal dexamethasone implant for the treatment of macular 
oedema (MO) related to retinal vein occlusion (RVO). Group 4, Intravitreal 
ocriplasmin for the treatment of vitreomacular traction (VMT) and macular hole 
(MH). Data from base-line, and follow-up after 3, 6, and 12 months was used in 
the analysis. Primary outcomes were MP light threshold sensitivity, CRT and 
VA. T-test and ANOVA computations did not show significant difference with 
LTS and the other studied variables. However, Pearson’s coefficient correlations 
showed higher levels of agreement between microperimetry FS indices and VA 
outcomes. This reinforce the importance to include retinal function variables in 
macular treatment studies, as such variables may represent subclinical 
indicators, not anatomically perceived with OCT examinations. Although FS 
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showed a better correlation to VA than retinal sensitivity and thickness, we have 
observed that the variety of changes in FS classification, according to the Fujii 
scale (Fujii et al., 2002), may not correspond to the level of change in FS indices 
P1 and BCEA, suggesting a re-definition of a new fixation stability 
classification. Of particular importance was the analysis of data on central retinal 
values with both OCT and MP. This analysis showed that in patients with non-
foveal fixation, the lack of perception of eccentric fixation by operators, may 
lead to examination outcomes with wrong estimates, where eccentric values 
wrongly deemed to represent central information. 
 
In recent years, a modified version of the MAIA, the S-MAIA, has become 
available allowing for light threshold sensitivity measurements in scotopic 
conditions. This is in response to the perceived need of investigating independent 
threshold sensitivities of cone and rod photoreceptors, as it has been reported by 
some authors that multiple retinal diseases are associated with rod photoreceptor 
functional impairment (Pfau et al., 2017a), along with other reports that have 
described histological cone photoreceptor degeneration in macular pathologies 
like AMD (Shelley et al., 2009). One challenge for the practical application of 
scotopic microperimetry in clinical settings is the time taken for the patient to 
dark adapt, which in addition to the examination time, may increase patient’s 
fatigue, which has been reported to reduce patient’s capacity to fixate (Morales 
et al., 2013). For such reason, chapter 7 described the investigation of three 
different dark adaptation times, 10, 20 and 30 minutes, on scotopic 
microperimetry as well as assessing the test-retest repeatability of the S-MAIA 
for each dark adaptation time, exploring in addition, the extent of a practice 
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effect. The results suggest that the time of dark adaptation did have an impact on 
the outcome measure with preference for a period of 30 minutes dark adaptation. 
Furthermore, this study provides data which suggests that the scotopic MAIA 
produces repeatable and reliable measurements with no evidence of a significant 
learning effect, specifically when a pre-test for training purposes is performed. 
 
Finally, chapter 8 is dedicated to the investigation of the use of MP in the fixation 
training for eccentric visual rehabilitation with biofeedback technology in 
patients with loss of central vision. Biofeedback fixation training had been 
reported as a method to improve FS trough oculomotor exercises. However, the 
selection of the retinal locus target to perform such training had not been 
described previously. This study had the aim of studying the effectiveness of 
such technology and proposing guidelines for this rehabilitation method. In this 
section, the different variables responsible for unstable fixation, and the selection 
of the best eccentric functional retinal locus were studied. The definition of the 
best eccentric functional retinal locus, was of paramount importance in this 
chapter as it may lead to better outcomes also in other vision therapies commonly 
performed in low vision centres, whilst increasing possibilities for a better 
quality of life in patients with loss of central vision secondary to macular 
pathologies. The analysis included 67 patients with various irreversible 
pathologies affecting the foveal area. Outcomes included FS indices, 
classification of fixation, VA, and reading speed. At the end of the chapter, step 
by step instructions were proposed to standardised a methodology to perform 
this fixation training, with emphasis in the selection of the best retinal locus 
aiming for effective therapeutic results. At the time of this thesis writing period, 
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the publication of this investigation had been accepted with minor amendments 
of the submitted manuscript.  
 
 
9.2 Limitations and Potential Future Directions 
 
Although this project has contributed to a better understanding of the assessment 
of retinal function and therapeutic capabilities of microperimetry technology, it 
is still possible to carry out further investigations. This section is dedicated to 
the identification of the limitations of this research work, followed by the 
suggested recommendations for future research: 
 
For project a) MP in the monitoring of macular diseases: 
• The number of participants for each study group was small and 
unbalanced. Therefore, it is recommended to proceed with further 
research with a higher number of participants for each study group with 
the purpose to increment the statistical power of the results. 
• The MP stimuli grid was the standard macular assessment grid available 
in the MAIA instrument, however such grid was designed to differentiate 
normal vs abnormal macular function, which may not be the ideal grid to 
monitor the progression of different pathologies affecting the macula and 
cannot be correlated with any standard macular test as those found in 
OCT instruments. For such reason, it is suggested to design a dedicated 
MP stimuli grid which can be correlated with all 9 sections of the ETDRS 
distribution. 
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• An important limitation of this work comes with the use of the automatic 
operation mode of the MAIA, which may misplace the centre of the 
stimuli grid over a non-foveal location. Therefore, it is suggested to 
create a methodology to assure that both OCT and MP instruments 
perform examinations accurately centred on the fovea centralis. 
• If central retinal thickness is intended to be correlated with MP outcomes, 
then a mean quantification of stimuli located over the foveal area should 
be performed. In case of the MAIA standard grid, this corresponds to the 
inner ring of 12 stimuli located 1° from the central stimuli, in addition to 
the central stimuli itself. 
 
For project b) MP fixation training for eccentric visual rehabilitation. 
• An important limitation of this study was the number and stratification 
of patients. Bilateral macular atrophy may be present in different 
dimensions and at different ages, therefore a large number of study 
subjects divided in several subgroups is recommended. 
• This was an interventional unmask trial which may performed by a single 
researcher which may lead to important bias during the study process. 
For such reason a multi-site study design performed by naïve operators 
with no, or minor, experience in visual rehabilitation must be perform to 
reduce bias. 
• A crucial limitation of this study is the lack of a control group. It is well 
known that patients with low vision conditions in the same visual acuity 
group may have remarkably different psychophysical characteristics, 
however it is suggested the inclusion of a control group with the purpose 
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to compare MP fixation training outcomes with other eccentric vision 
techniques available today in low vision practices. 
 
Other meaningful recommendations for future research are the 
following: 
• A randomization methodology should be applied to select patients on 
each group. 
• A study with different subgroups according to pathology should be 
included. 
• Different therapy time settings as well as resting time should be tested. 
• Results should be presented in different timelines, i.e. 3, 6, 12 and 24 
months. 
• A longer follow up examination must be included to evaluate 
permanence of therapy outcomes and compared them with controls. 
• A precise quantification of scotomata area should be included in the 
methodology. 
• The study must be registered in any recognised site for clinical trials to 
increase monitoring and proof of principles reliability. 
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9.3 General Conclusions 
 
The first aim of this study was to assess the benefit of MP functional analysis in 
clinical practice for patients undergoing clinical treatments, related to 
pathologies affecting central vision. This was achieved in full. A better 
understanding of MP technology and its clinical applications and limitations has 
been reached. Furthermore, a series of recommendations have been set to 
improve the use of microperimetry devices, which will increase substantially 
accuracy in further clinical trials where MP is included. 
 
The second aim was related to the therapeutic capabilities of MP in the 
rehabilitation of eccentric vision, studying the effectiveness of such technology 
and proposing guidelines for this rehabilitation method, with the aim of allowing 
the use of this technique to a wider pool of eye specialists with minimal 
experience in eccentric vision rehabilitation. This was also achieved in full as 
the study has created guidelines, which certainly after its publication, will be of 
significant benefit for MP users worldwide, who may be looking forward to offer 
this therapeutic technique to patients with irreversible central vision loss. 
Despite the fact that this technique has proven to be effective in a clinical 
environment, it leaves open queries regarding the effective benefit in regular 
daily activities. Furthermore, a couple of additional questions remain open, e.g. 
the majority of patients clinically diagnosed with low vision have still some 
degrees of remaining binocular vision, whilst the MP instrument, in contrast, is 
a monocular system. Therefore, the significant lack of understanding concerning 
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binocular visual function after monocular fixation training remains open. On the 
other hand, this therapeutic technique is possible only in a clinical environment, 
whilst the majority of low vision patients may have mobility difficulties, limiting 
its benefit only to those patients able to assist constantly and for long period of 
times a clinical setting. This leaves open opportunities for developments of 
similar equipment/techniques to be use in a home environment. 
 
People with macular degeneration, and other retinal pathologies affecting the 
central vision, will derive significant benefit from our research. This research 
will allow patients and clinical practitioners to better understand visual function 
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